Topics

Cancer Biomarkers In Precision Oncology

Cancer Immunotherapy DNA Metabolism And Repair Tumor Microenvironment

Cancer biomarkers in precision oncology are measurable tumor or host features that guide diagnosis, prognosis, treatment selection, response monitoring, and resistance assessment. The field matured when molecular abnormalities became therapeutic decision points rather than descriptive cancer features: BCR-ABL activity supported targeted inhibition in chronic myeloid leukemia, EGFR mutations identified gefitinib-responsive lung cancers, and BRAF V600E defined a melanoma population responsive to mutant BRAF inhibition. These studies established biomarker-driven oncology as a central life-science strategy for connecting cancer genomics, targeted therapy, and clinical decision-making[1][2][3].

Mechanistically, precision oncology biomarkers act by identifying activated oncogenic dependencies, defective repair states, immune-response features, or circulating tumor signals. BCR-ABL, EGFR, ALK, and BRAF biomarkers match tumors to kinase inhibitors; mismatch-repair deficiency and microsatellite instability identify tumors with sensitivity to PD-1 blockade; tumor mutational burden can predict pembrolizumab benefit across advanced solid tumors; and circulating tumor DNA enables noninvasive tracking of tumor genotype, clonal evolution, treatment response, and acquired resistance. These mechanisms connect biomarker testing with kinase signaling, DNA repair, antigenicity, immune checkpoint response, and tumor evolution[1][2][3][4][5][6][7].

Disease applications now span hematologic cancer, lung cancer, melanoma, colorectal cancer, breast cancer, and tumor-agnostic therapy development. Imatinib demonstrated molecularly targeted treatment in BCR-ABL-positive chronic myeloid leukemia, EGFR mutation testing reshaped non-small-cell lung cancer treatment, ALK rearrangement guided crizotinib therapy, vemurafenib improved outcomes in BRAF V600E melanoma, and mismatch-repair deficiency predicted clinical benefit from immune checkpoint blockade. Liquid biopsy extends these applications by detecting actionable alterations and resistance mechanisms when tissue biopsy is limited or repeated sampling is needed[1][2][3][4][5][7][8].

The main challenges are biomarker heterogeneity, assay variability, tumor evolution, low-frequency resistance clones, limited tissue, uncertain actionability, and unequal access to validated genomic testing. Future precision oncology needs integrated tissue and liquid biopsy workflows, standardized interpretation, molecular tumor boards, prospective validation of multi-omic biomarkers, and trials that test biomarker-matched combinations instead of isolated targets. The most defensible prospect is a clinically grounded model in which biomarkers select therapy, monitor response, detect resistance, and refine treatment sequencing without assuming that every molecular alteration is therapeutically actionable[6][7][8][9][10].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Enzyme
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-10201 Sorafenib
Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma.
Raf   VEGFR   FLT3   Autophagy   Apoptosis   STAT   Akt   MMP   Cadherin   p38 MAPK   ERK   MEK   PI3K   PARP   Bcl-2 Family   Ephrin Receptor   PDGFR  
Gastric Cancer   Liver Cancer   Ovarian Cancer   Digestive System Inflammation   Small Cell Lung Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   Metastatic Colorectal Cancer   Metastatic Prostate Cancer   Multiple Myeloma   Metastatic Pancreatic Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Obesity   Lung Fibrosis  
316
HY-50895 Gefitinib
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
EGFR   Autophagy   Apoptosis  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Lipid Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Metastatic Breast Cancer   SARS-CoV-2 Infection  
222
HY-15772 Osimertinib
Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
EGFR  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Glucose Metabolism   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
208
HY-N0565B Doxycycline hyclate
Doxycycline hyclate, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline hyclate shows antibacterial activity and anti-cancer cell proliferation activity. Doxycycline hyclate can be used to construct gene expression regulation models.
Antibiotic   MMP   Bacterial   Parasite  
Breast Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Staphylococcus Aureus Infection   Chlamydia Infection   Lung Fibrosis  
197
HY-N0565 Doxycycline
Doxycycline, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor. Doxycycline shows antibacterial activity and anti-cancer cell proliferation activity.
MMP   Bacterial   Antibiotic   Parasite  
Breast Cancer   Pancreatic Cancer   Viral Infection   Parasitic Infection   Pain   SARS-CoV-2 Infection   Staphylococcus Aureus Infection   Chlamydia Infection   Lung Fibrosis  
197
HY-10181 Dasatinib
Dasatinib (BMS-354825) is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib also induces apoptosis and autophagy, and can cross the blood-brain barrier.
Bcr-Abl   Src   Autophagy   Apoptosis   Ligands for Target Protein for PROTAC  
Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Pain   Digestive System Inflammation   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Lung Fibrosis  
183
HY-50896 Erlotinib
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
EGFR   OAT   ERK   GSK-3   β-catenin  
Gastric Cancer   Pancreatic Cancer   Renal Disease   Non-Small Cell Lung Cancer   Lung Adenocarcinoma  
147
HY-50946 Imatinib Mesylate
Imatinib Mesylate (STI571 Mesylate) is an orally active tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases.
c-Kit   Bcr-Abl   PDGFR   Autophagy  
Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Alzheimer's Disease   Parkinson's Disease   Lung Fibrosis  
130
HY-15463 Imatinib
Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.
Bcr-Abl   PDGFR   c-Kit   SARS-CoV   Autophagy  
Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Alzheimer's Disease   Parkinson's Disease   Lung Fibrosis  
130
HY-13520 Nocodazole
Nocodazole (Oncodazole) is a rapidly-reversible inhibitor of microtubule. Nocodazole binds to β-tubulin and disrupts microtubule assembly/disassembly dynamics, which prevents mitosis and induces apoptosis in tumor cells. Nocodazole inhibits Bcr-Abl.
Bcr-Abl   Apoptosis   Microtubule/Tubulin   Autophagy   Mitosis  
Digestive System Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Alzheimer's Disease   Parkinson's Disease  
130
HY-10261 Afatinib
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
EGFR   Autophagy   Apoptosis   c-Met/HGFR   Akt   p38 MAPK  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   Digestive System Inflammation   Hepatitis C Virus Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
113
HY-12270 T-5224
T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription.
AP-1   MMP  
Pancreatic Cancer   Depression   Pain   Lung Fibrosis  
109
HY-12057 Vemurafenib
Vemurafenib (PLX4032) is a first-in-class, selective, potent inhibitor of B-RAF kinase, with IC50s of 31 and 48 nM for RAFV600E and c-RAF-1, respectively. Vemurafenib induces cell autophagy.
Raf   Autophagy  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Obesity  
105
HY-L005 Epigenetics Compound Library
Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases. MCE provide a unique collection of 2,031 epigenetics-related compounds that can be used in the research of the related diseases.

Signaling Pathway Targeting Libraries

102
HY-50898 Lapatinib
Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
EGFR   Autophagy   Ferroptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
100
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,237 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

100
HY-10331 Regorafenib
Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity.
VEGFR   Autophagy   PDGFR   Raf   RET   c-Kit   FGFR   Tie  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
97
HY-14596 Genistein
Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR) inhibitor which acts as a chemotherapeutic agent against different types of cancer, mainly by altering apoptosis, the cell cycle, and angiogenesis and inhibiting metastasis.
EGFR   Autophagy   Apoptosis   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Lung Cancer   Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection   Hepatitis C Virus Infection   Obesity  
94
HY-L048 Antifungal Compound Library
The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of efflux pump proteins, overexpression and changes in drug targets and biofilm formation, emphasizing the importance of discovering new antifungal drugs and therapies. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, such as the combination of antifungal drugs, development of new formulations for antifungal agents and modifications to the chemical structures of traditional antifungals, etc. MCE offers a unique collection of 585 compounds with validated antifungal activities. MCE antifungal compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.

Disease Focused Libraries

87
HY-L077 Anti-Pancreatic Cancer Compound Library
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 4,336 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Disease Focused Libraries

85
HY-L123 Human Metabolite Library
Human metabolism is an integral part of cellular function that reflects individual differences in health, disease, diet, and lifestyle. Many health conditions such as obesity, diabetes, hypertension, heart disease, and cancer are associated with abnormal metabolic states. In the pathological state of the human body, metabolic pathways are significantly altered, resulting in aberrant levels of intermediates or end-products that can be viewed as potential diagnostic biomarkers or even therapeutic targets. Therefore, detection, identification and quantification of human metabolites are very important for drug metabolism research in drug development. MCE offers a unique collection of 6,767 human metabolites, including endogenous metabolites and exogenous metabolites, covering multiple structure types, such as lipids, amino acids, nucleic acids, carbohydrates, organic acids, biogenic amines, vitamins,. MCE Human Metabolites Library is a helpful tool for studying the relationship between diseases and metabolism.

Metabolism Focused Libraries

85
HY-14660 Dabrafenib
Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively.
Raf   CDK  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer  
84
HY-L034 Anti-Aging Compound Library
Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. MCE Anti-Aging Compound Library contains 7,771 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Disease Focused Libraries

84
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L080 Targeted Therapy Drug Library
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases. MCE carefully collects a unique of 106 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

Disease Focused Libraries

84
HY-L151 PROTAC Library
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy. MCE supplies a unique collection of 544 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

Compound Characteristic Classified Libraries

84
HY-L005M Epigenetics Compound Library Mini
Epigenetics involves heritable phenotypic changes that occur without alterations to the underlying DNA sequence. Key mechanisms include DNA methylation, histone modifications, and regulation by small non-coding RNAs such as microRNAs. By modifying DNA, histones, or RNA—while leaving their primary sequences intact—these processes influence molecular function and regulation, thereby playing critical roles in cellular differentiation, embryonic development, gene expression control, aging, and diseases such as cancer. MCE provide a unique collection of 295 epigenetics-related compounds. For each regulatory target and its subtype, 3 to 5 highly specific representative compounds have been retained, which can be used in epigenetic and related disease research.

Signaling Pathway Targeting Libraries

83
HY-L074 Anti-Breast Cancer Compound Library
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,404 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Disease Focused Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L097 Animal Disease Model Inducer Library
Animal disease models are used in a variety of settings in basic research, such as studies on mechanisms of disease progression and evaluation new drugs. Animal models can be broadly classified into five categories: 1) experimental, 2) spontaneous, 3) negative, 4) orphan, 5) genetically engineered. Experimental models, which are induced artificially in the laboratory, are most common. Some small molecular compounds are usually used as inducers for animal models, such as Ceruletide for inflammatory model, Azoxymethane for tumor model. These inducers are useful tool in building animal models. MCE offers a unique collection of 52 animal model inducers, involving inflammatory model, tumor model, nervous disease model, etc. MCE Animal Disease Model library is a powerful tool for the establishment of animal disease models.

Compound Characteristic Classified Libraries

83
HY-L137 Molecular Glue Compound Library
Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention. Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy. MCE supplies a unique collection of 124 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

Compound Characteristic Classified Libraries

83
HY-L152 F-Fragments Library
19F-NMR has proved to be a detection mode in fragment-based drug discovery (FBDD) for studies of protein structure and interactions. 19F shows high sensitivity for NMR detection, and the exquisite sensitivity of 19F chemical shifts and linewidths to ligand binding all make it a valuable approach in FBDD.F (Fluorine) -Fragments can be used for 19F-NMR detection after binding to target proteins, and can be used as an effective 19F-NMR tool for FBDD. MCE designs a unique collection of 5,077 F-fragments, all of which obey a heuristic rule called the “Rule of Three (RO3)”, in which molecular weight ≤300 Da, the number of hydrogen bond donors (H-donors) ≤3, the number of hydrogen bond acceptors (H-acceptors) is ≤3 and cLogP is ≤3. This F-fragments library is an important source of lead-like drugs.

According to Fragment Structures

83
HY-L161 Cytokine Inhibitors Library
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases. MCE designs a unique collection of 1,416 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.

Signaling Pathway Targeting Libraries

83
HY-L203 Methylation Compound Library
Methylation is an epigenetic modification mechanism that involves adding methyl groups to molecules such as DNA and histones, which can alter gene expression without changing the DNA sequence. This process is catalyzed by enzymes such as DNA methyltransferases (DNMTs) and histone methyltransferases (HMTs), and can be reversed by demethylases. The balance of methylation and demethylation is crucial for maintaining cellular function and genomic stability. Abnormal regulation of methylation may lead to a variety of diseases, including cancer, neurological disorders, and developmental abnormalities. A deep understanding of the molecular mechanisms of methylation metabolism is essential for developing therapeutic strategies for diseases associated with methylation dysregulation. MCE contains 351 compounds targeting methylation/demethylation enzymes, which is of significant value for studying the pathways of methylation metabolism and exploring their mechanisms of action in diseases.
83
HY-L204 Lactic Acid Metabolic Compound Library
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism. MCE contains 582 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
83
HY-L215 Mass Spectrometry Human Metabolite Library
Metabolomics, positioned as the systemic characterization of small-molecule metabolites within biological systems, has emerged as an indispensable analytical platform in both fundamental research and translational applications across plant sciences, microbial biotechnology, and biomedical investigations. Functioning as a critical component in multi-omics integration, this discipline deciphers the intricate molecular networks operating downstream of genomic, transcriptomic, and proteomic regulation, thereby capturing the dynamic biochemical phenotype closest to organismal functionality. The metabolome, comprising endogenous compounds with molecular weights typically below 1500 Da, serves as the functional readout of cellular processes and environmental interactions, where perturbations in metabolic networks are frequently implicated in disease pathogenesis. Such unique attributes have propelled metabolomics into a pivotal role in pharmacological research, particularly in target deconvolution, pharmacodynamic assessment, and mechanistic elucidation of pathological processes. MCE can provide 6,077 mass spectrometry human metabolites that can be used for metabolite identification and quantification, functional cell detection and phenotypic screening of mass spectrometry.

Metabolism Focused Libraries

83
HY-L244 High-Efficiency Gene Editing Compound Library
In this era of rapid advancement in gene-editing technology, the CRISPR-Cas system, with its powerful programmability, is leading a transformation in life sciences research. It enables efficient and precise targeted modification of an organism's genome, providing a robust tool for studying gene function, treating genetic diseases, and improving crop varieties. However, bottlenecks such as insufficient editing efficiency, low homologous directed repair efficiency, and potential off-target risks remain major challenges in achieving precise genetic modifications and developing gene therapies. To overcome these limitations, the MCE High-Efficiency Gene Editing Compound Library systematically includes 761 small molecules that are known or have the potential to enhance gene-editing efficiency. These compounds work by targeting and modulating the DNA damage repair network, mechanistically inhibiting non-homologous end joining, promoting homologous directed repair, or regulating chromatin states and cellular responses, thereby significantly optimizing editing outcomes. This library is suitable for developing "CRISPR-small molecule" combination therapy strategies, improving gene-editing efficiency, and providing a powerful tool for in-depth research into the mechanisms of DNA damage repair in gene editing.

Signaling Pathway Targeting Libraries

83
HY-L248 RNA Binding Bioactive Compound Library
The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development. The MCE RNA-targeted bioactive compound library contains 858 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

Signaling Pathway Targeting Libraries

83
HY-L263 Energy Metabolites Library
Energy metabolism is the most fundamental biochemical process in living organisms, encompassing glycolysis, the TCA cycle, oxidative phosphorylation, the pentose phosphate pathway, and fatty acid oxidation. These core pathways directly regulate cell survival, proliferation, differentiation, and apoptosis. Dysregulation of energy metabolism is closely linked to major diseases including cancer, diabetes, obesity, cardiovascular diseases, neurodegenerative disorders, and ischemia‑reperfusion injury. Targeting these metabolic pathways has become a frontier in drug discovery and mechanistic research. The MCE Energy Metabolite Compound Library features 89 structurally defined small‑molecule compounds. It covers energy substrates, pathway intermediates, coenzymes and redox carriers, nucleotide derivatives, and microenvironmental modulators. This library is applicable to research areas including tumor metabolism, insulin resistance, mitochondrial dysfunction, oxidative stress, neuroprotection, and cardiometabolic diseases, providing a high‑quality tool for mechanistic studies, biomarker discovery, and high‑throughput drug screening.

Signaling Pathway Targeting Libraries

83
HY-L264 DNA Damage Repair Inhibitor Library
DNA damage response (DDR) is a fundamental mechanism for maintaining genomic stability. When DNA damage occurs, such as single- or double-strand breaks or replication fork stalling, cells rely on key proteins including ATM, ATR, PARP, and DNA-PK to sense the damage and transmit signals, thereby regulating DNA repair, cell-cycle arrest, and cell death. Inhibition of specific DNA repair or checkpoint pathways can prevent tumor cells from effectively repairing accumulated DNA damage, ultimately leading to tumor cell death. MCE DNA Damage Repair Inhibitor Library contains 1,544 compounds, focusing on key nodes involved in DNA damage response and DNA repair. The library covers multiple DNA repair and cell-cycle checkpoint pathways, providing a systematic compound screening tool for research on precision oncology, synthetic lethality, drug resistance mechanisms, and chemo- or radiosensitization.
83
HY-L907 MCE Kinase Hinge Binder Fragment Library
The most prominent mechanism of action of kinase inhibitors is their competition with ATP by binding to the hinge region of the kinase protein. Once the kinase is blocked by an inhibitor, it loses the ability to transfer phosphate groups from ATP to other molecules, resulting in the loss of kinase activity. The hinge-binding region of kinase inhibitors mimics the interaction pattern between the ATP nucleobase and the kinase. MCE extracted thousands of kinase inhibitors from the ChEMBL database and isolated their molecular fragments. In certain cases, the amino and amide groups on the molecular fragments are crucial for binding in the hinge region. Therefore, we enhanced the diversity of the collected results by adding these two groups to unoccupied positions on the ring system. Subsequently, the fragments were assessed for their hinge region binding ability via docking at distinct kinases, we also applied pharmacophore constraints to ensure interactions with key amino acids in the kinase hinge region, ultimately obtaining kinase-related molecular fragments. MCE provides over 12,373 kinase fragment molecules that meet the above requirements and are available off the shelf, serving as an effective tool for screening and developing drugs targeting kinases.

Functional Fragment Libraries

83
HY-L918 Molecular Glue-like Compound Library
Targeted Protein Degradation (TPD) is a novel and promising approach to drug development. It shows great potential for targeting proteins traditionally considered "undruggable" due to the lack of enzymatic function and absence of binding sites by tagging them for degradation or recruiting natural degradation mechanisms. Molecular glues are a type of small-molecule degraders that primarily induce novel interactions between E3 ubiquitin ligases and target proteins, forming ternary complexes that lead to protein ubiquitination and subsequent proteasomal degradation. Compared with PROTACs, molecular glues generally have lower molecular weights, higher cell permeability, and better drug-like properties. Additionally, the design of molecular glues is relatively simple, without the requirements for complex linkers and ligand optimization. As a result, molecular glues have gradually emerged as a promising therapeutic approach for various diseases. Multiple types of molecular glues have been reported previously. Analysis of co-crystal complex structures reveals that CRBN-related molecular glues are more versatile. Therefore, MCE researchers select active molecules related to these targets as probes for artificial intelligence (AI) screening.Subsequently, molecular docking technology was used to verify whether the screened molecules retained the key pharmacophore features. Ultimately, we obtained 317 molecular glue analogs, and these compounds serve as powerful tools for the research of molecular glues.

Focused and target libraries

83
HY-L919 MCE CNS BBB Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB). The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering. Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.

Focused and target libraries

83
HY-L934 CRBN Ligand Library
CRBN, namely cereblon, is the substrate recognition subunit of the E3 ubiquitin ligase complex in the ubiquitin-proteasome system. A CRBN ligand library refers to a collection of numerous fragments that can specifically bind to the CRBN protein. These ligands are mostly designed based on validated CRBN-binding warheads and modified through AI-driven molecular generation optimization systems. They not only include classic lenalidomide-derived structures but also cover novel non-lenalidomide scaffolds. After drug-likeness filtering, these ligands exhibit structural diversity and favorable druggable properties. They can be further optimized and modified to facilitate the development of novel molecular glue degraders, accelerate the discovery of molecular glues that induce interactions between CRBN and new substrate proteins, and enable the exploration of novel CRBN substrates for identifying previously unknown CRBN-binding proteins. MCE compiles 122 fragments that can specifically bind to the CRBN protein, with molecular weights ranging from 200 to 500. Compounds developed based on the library ligands target multiple disease targets such as cancer and autoimmune diseases, further advancing the development of Molecular Glues and PROTACs therapeutic agents.

Featured Fragment Libraries

83
HY-L935 Molecular Glue POI binding Fragment library
POI (Protein of Interest) refers to the target protein, namely the disease-causing protein or key functional protein that undergoes degradation or functional modulation in molecular glue-mediated processes. The Molecular Glue POI Library consists of a series of fragments that can specifically bind to different types of POIs. As key components of molecular glues, these ligands form stable interactions with target proteins, laying the foundation for molecular glues to induce the interaction between POIs and E3 ubiquitin ligases. The covered POIs include various types such as cancer-associated GSPT1, androgen receptors, and abnormally aggregated proteins linked to neurodegenerative diseases. This fragment library can be applied to the screening and optimization of targeted protein degraders. By screening ligands with high affinity and strong selectivity for specific POIs from the library, core structures can be identified to develop novel molecular glues. For instance, optimization of ligands targeting GSPT1 has yielded molecular glue degraders with enhanced degradation activity. Since many POIs are difficult to drug due to the lack of traditional small-molecule binding pockets, some ligands in the POI Ligand Library can modulate such POIs by inducing protein-protein interactions, thereby further expanding the scope of drug discovery for undruggable targets. MCE has compiled a POI Fragment Library comprising thousands of POI fragments with molecular weights ranging from 150 to 400. This compound library can be widely applied in Molecular Glue research and development.

Featured Fragment Libraries

83
HY-L936V0 Molecular Glue Virtual Library
Molecular Glue Virtual Library is constructed using generative AI technology, integrating the structural features, activity data of known molecular glues, and interaction information of ternary complexes (target protein-E3-molecular glue). Endowed with structural novelty, drug-likeness, diversity and synthesizability, it is applicable to molecular glue-based AI drug screening and large-scale virtual screening. MCE builds this library based on high-quality molecular building blocks by virtue of robust computing power, coupled with rigorous reaction rules and optimized compound generation strategies. To ensure library quality, molecules with high synthetic difficulty, poor drug-likeness, PAINS and other undesirable molecules are excluded first. Subsequently, scaffold-based compound analysis is performed to screen drug-like diverse molecules for synthesizability evaluation; those with excessively high synthetic difficulty are removed, ultimately forming a large-scale molecular glue virtual library with structural diversity, synthesizability and drug-likeness. Compounds in the library can be synthesized in only 1-2 chemical reaction steps. With MCE’s experienced chemical synthesis team, custom synthesis of different scales from milligram to kilogram can be easily achieved to meet diverse customer needs.

AI-enabled Libraries

83
HY-16141 Cilengitide
Cilengitide (EMD 121974) is an integrin (integrin) inhibitor with blood-brain barrier permeability, with IC50 values against human targets as follows: 0.61 nM for αvβ3, 8.4 nM for αvβ5, 14.9 nM for α5β1, 5400 nM for αIIbβ3, 2050 nM for αvβ6, 2350 nM for αvβ8. Cilengitide inhibits the binding of integrins to vitronectin, fibronectin, fibrinogen and LAP (TGF-β), and serves as an internal standard for solid-phase integrin binding assays. Cilengitide inhibits tumor cell viability, induces apoptosis, reduces the phosphorylation levels of STAT3, AKT and mTOR, downregulates the expression of PD-L1, inhibits cell viability and angiogenesis, regulates anti-tumor immune responses and slows tumor growth. Cilengitide can be used in research related to glioblastoma, melanoma, advanced solid tumors and refractory brain tumors.
Integrin   TGF-β Receptor   Apoptosis   PD-1/PD-L1   STAT   Akt   mTOR  
Melanoma   Glioblastoma  
75
HY-P7058 TNF-alpha/TNFSF2 Protein, Human
Tumour Necrosis Factor alpha (TNF alpha) is a potent pro-inflammatory cytokine. TNF alpha binds to its receptors, mainly TNFR1 and TNFR2, and then transmits molecular signals for biological functions such as inflammation and cell death. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis. Anti-TNF-α MAb significantly suppresses the tumor development in colitis-associated cancer (CAC) mouse. TNF alpha as a proneurogenic factor activates the SAPK/JNK Pathway and can facilitate neuronal replacement and brain repair in response to brain injury. TNF-alpha/TNFSF2 Protein, Human is a recombinant protein consisting of 157 amino acids (V77-L233) and is produced in E. coli.

Species: Human; Source: E. coli

Cytokines and Growth Factors TNF Superfamily Neurotrophic Factors TNF Superfamily Ligands TNF-alpha

74
HY-P9907 Trastuzumab
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR   ADC Antibodies  
Non-Small Cell Lung Cancer   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
71
HY-15768 Ilomastat
Ilomastat (GM6001) is a potent and broad spectrum matrix metalloprotease (MMP) inhibitor, inhibits MMPs (IC50s, 1.5 nM for MMP-1; 1.1 nM for MMP-2; 1.9 nM for MMP-3; 0.5 nM for MMP-9), with a Ki of 0.4 nM for human skin fibroblast collagenase (MMP-1).
MMP  
Pancreatic Cancer   Pain   Lung Fibrosis   Rheumatoid Arthritis  
67
HY-12047 Ponatinib
Ponatinib (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively.
Bcr-Abl   PDGFR   VEGFR   FGFR   Src   Autophagy  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Pain   Non-Small Cell Lung Cancer   Acute Lymphoblastic Leukemia   Chronic Myelogenous Leukemia   Pancreatic Ductal Adenocarcinoma   Alzheimer's Disease   Parkinson's Disease   Lung Fibrosis  
57
HY-P9905 Cetuximab
Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a Kd of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity.

Species: Human

Radionuclide-Drug Conjugates (RDCs)   EGFR  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
57
HY-10159 Nilotinib
Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
Bcr-Abl   Autophagy  
Leukemia/Lymphoma/Myeloma   Alzheimer's Disease   Parkinson's Disease  
53
HY-10320 Doramapimod
Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC50 for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (Kd=0.1 nM). Doramapimod also inhibits B-Raf with an IC50 of 83 nM.
p38 MAPK   Raf   Autophagy  
Lung Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Neurodegenerative Disease   Depression   Pain   SARS-CoV-2 Infection   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
53
HY-15605 Encorafenib
Encorafenib (LGX818) is a highly potent BRAF inhibitor with selective anti-proliferative and apoptotic activity in cells expressing BRAFV600E (EC50=4 nM).
Raf  
Colorectal Cancer   Liver Cancer   Pancreatic Cancer   SARS-CoV-2 Infection   Obesity  
47
HY-P9904 Atezolizumab
Atezolizumab (MPDL3280A) is a selective humanized monoclonal IgG1 antibody against programmed death ligand 1 (PD-L1), used for cancer research.

Species: Human

PD-1/PD-L1   Apoptosis   Autophagy  
Colorectal Cancer   Liver Cancer   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
42
HY-P9902 Pembrolizumab
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
37
HY-19991 BMS-1
BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM).
PD-1/PD-L1   Apoptosis  
Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
34
HY-19745 BMS-202
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC50 of 18 nM and a KD of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity.
PD-1/PD-L1   Apoptosis  
Neurological, Eye or Ear Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
27
HY-P99144 Anti-Mouse PD-1 Antibody (RMP1-14)
Anti-Mouse PD-1 Antibody (RMP1-14) is an anti-mouse PD-1 IgG2a antibody. Anti-Mouse PD-1 Antibody (RMP1-14) can be used for the study of colon carcinoma.

Species: Mouse

PD-1/PD-L1  
Cancer   Inflammation or Immune System Disease  
27
HY-10158 Bosutinib
Bosutinib is an orally active Src/Abl tyrosine kinase inhibitor with IC50 of 1.2 nM and 1 nM, respectively.
Src   Bcr-Abl   Autophagy  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Pain   Metastatic Breast Cancer   Chronic Myelogenous Leukemia   Non-Hodgkin Lymphoma   Multiple Myeloma   Glioblastoma   Alzheimer's Disease   Parkinson's Disease   Lung Fibrosis  
25
HY-K6002 Basement Membrane Matrix

MCE Basement Membrane Matrix is primarily composed of natural basement membrane matrix extracted from mouse tumors.This product is mainly used for studies of tumor invasion, angiogenesis and organoids culture while avoiding color interference in subsequent experiments.

Cell Biology 3D Cell Culture Basement Membrane Matrix

25
HY-13264 Degrasyn
Degrasyn (WP1130) is a cell-permeable deubiquitinase (DUB) inhibitor, directly inhibiting DUB activity of USP9x, USP5, USP14, and UCH37. Degrasyn has been shown to downregulate the antiapoptotic proteins Bcr-Abl and JAK2.
Deubiquitinase   Bcr-Abl   Autophagy   Apoptosis  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   Alzheimer's Disease   Parkinson's Disease  
23
HY-P9903 Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

Species: Human

PD-1/PD-L1  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
23
HY-E70005A Collagenase, Type I
Collagenase, Type I is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type I breaks down collagens 1, 3, 7, 8, 10, gelatin, proteoglycans, aggrecan.
MMP  
21
HY-E70005D Collagenase IV, Clostridium histolytica
Collagenase, Type IV (EC 3.4.24.3) is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type IV degrades type IV collagen and type VII collagen, the main components of the basement membrane, and can also decompose basement matrix and elastin.
MMP  
21
HY-K6001 Basement Membrane Matrix (Phenol Red)

MCE Basement Membrane Matrix (Phenol Red) is primarily composed of a natural basement membrane matrix derived from mouse tumors. This product is mainly for studies of tumor invasion, angiogenesis, and organoid culture.

Cell Biology 3D Cell Culture Basement Membrane Matrix

21
HY-114409 GB1107
GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. GB1107 reduces human and mouse lung adenocarcinoma growth and blocks metastasis in the syngeneic model.
Galectin  
Cancer   Lung Fibrosis  
20
HY-P99145 Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2)
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse PD-L1/B7-H1 IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer.

Species: Mouse

PD-1/PD-L1  
Colorectal Cancer  
20
HY-B0239 Chloramphenicol
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research.

Source: Streptomyces venezuelae

Antibiotic   Bacterial   HIF/HIF Prolyl-Hydroxylase   VEGFR   Autophagy   Apoptosis   Beclin1   JNK   Akt   MMP  
Infection   Respiratory Disease   Non-Small Cell Lung Cancer  
19
HY-19756 OTX008
OTX008 is a selective inhibitor of galectin-1.
Galectin  
Cancer  
18
HY-156498 RMC-7977
RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRASG12C cancer models, and demonstrates good tolerability across various RAS cancer models.
Ras   ERK   Raf   Ribosomal S6 Kinase (RSK)   AMPK   Apoptosis   PARP  
18
HY-113466 4-Hydroxynonenal
4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of acetaldehyde dehydrogenase 2 (ALDH2). 4-Hydroxynonenal can modulate a number of signaling processes mainly through forming covalent adducts with nucleophilic functional groups in proteins, nucleic acids, and membrane lipids. 4-Hydroxynonenal plays an important role in cancer through mitochondria.
Aldehyde Dehydrogenase (ALDH)   Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease   Cardiovascular Disease  
18
HY-104010 Asciminib
Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.
Bcr-Abl  
Leukemia/Lymphoma/Myeloma   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease  
16
HY-E70005B Collagenase, Type II
Collagenase, Type II is a microbially derived matrix metalloproteinases (MMPs) and zinc peptidase. Collagenase, Type II breaksdown collagens1, 3, 5, 7, 8, 10, fibronectin, gelatin, aggrecann.
MMP  
16
HY-B0425A Novobiocin sodium
Novobiocin (Albamycin) sodium is a potent and orally active antibiotic. Novobiocin sodium also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin sodium has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin sodium shows anti-orthopoxvirus activity.

Source: Streptomyces niveus

Antibiotic   DNA/RNA Synthesis   HSP   Apoptosis   Bacterial   Parasite  
Breast Cancer   Prostate Cancer   Ovarian Cancer   Bacterial Infection   Parasitic Infection  
14
HY-13024 Rebastinib
Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor, with IC50 values of 0.8 nM and 4 nM against Abl1WT and Abl1T315I, respectively. Rebastinib potently inhibits CYP2C8 (IC50 = 0.0533 μM) and CYP2C9 (IC50 = 2.54 μM). Rebastinib allosterically inhibits Tie2 with an IC50 of 0.63 nM. Rebastinib inhibits the transcriptional activity of FoxO1. Rebastinib inhibits SRC family kinases, KDR and FLT3 kinases. Rebastinib induces Apoptosis. Rebastinib exerts anti-tumor activity in breast cancer. Rebastinib exerts anti-angiogenic effects. Rebastinib increases myotube diameter and improves reduced contractility. Rebastinib can be used in research related to triple-negative breast cancer, luminal breast cancer, pancreatic neuroendocrine tumors, muscle atrophy, cancer cachexia, chronic myeloid leukemia, and B-lymphocytic leukemia.
Bcr-Abl   Cytochrome P450   Tie   FOXO   Src   FLT3   Apoptosis  
Pancreatic Cancer   Triple-Negative Breast Cancer   Muscular Dystrophy  
13
HY-19940 Olitigaltin
Olitigaltin (TD139) is a high-affinity Galectin-3 inhibitor with a Kd value of 14 nM. Olitigaltin inhibits the activity of the AKT/β-catenin pathway, induces Apoptosis, and downregulates SREBP1 expression. Olitigaltin enhances the phosphorylation level of ERK. Olitigaltin alleviates bleomycin (HY-17565A)-induced advanced pulmonary fibrosis in mice. Olitigaltin delays the onset of diabetes, and improves glucose tolerance and serum insulin levels. Olitigaltin alleviates liver injury. Olitigaltin maintains the structure of hippocampal excitatory synapses, restores γ-wave power in the hippocampal CA1 region, inhibits hippocampal neuroinflammation, and improves cognitive function in neuroinflammation models. Olitigaltin can be used in research related to thyroid cancer, idiopathic pulmonary fibrosis, type 1 diabetes, hepatitis, and cognitive dysfunction induced by neuroinflammation.
Galectin   Akt   β-catenin   Apoptosis   ERK  
Neurological, Eye or Ear Disease   Thyroid Cancer   Liver Disease   Type 1 Diabetes   Lung Fibrosis  
13
HY-138298 Trastuzumab deruxtecan (solution)
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer   Gastric Cancer  
12
HY-138298A Trastuzumab deruxtecan
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
Antibody-Drug Conjugates (ADCs)   EGFR  
Breast Cancer  
12
HY-148905 p-Aminophenylmercuric acetate
p-Aminophenylmercuric acetate is an organomercurial activator of matrix metalloproteinases (MMP). P-Aminophenylmercuric acetate participates in the activation and inhibition of MMP-8 by attacking protein sulfhydryl or inducing cysteine switching reaction. p-Aminophenylmercuric acetate promotes the shedding of betacellulin precursor (pro-BTC). p-Aminophenylmercuric acetate influences the binding of agonists and antagonists to the opiate receptor.
Cathepsin   MMP  
Infection  
11
HY-P70697 TNF-alpha/TNFSF2 Protein, Rat
Tumour Necrosis Factor alpha (TNF alpha) is a potent pro-inflammatory cytokine. TNF alpha binds to its receptors, mainly TNFR1 and TNFR2, and then transmits molecular signals for biological functions such as inflammation and cell death. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis. Anti-TNF-α MAb significantly suppresses the tumor development in colitis-associated cancer (CAC) mouse. TNF alpha as a proneurogenic factor activates the SAPK/JNK Pathway and can facilitate neuronal replacement and brain repair in response to brain injury .

Species: Rat; Source: E. coli

Cytokines and Growth Factors TNF Superfamily Neurotrophic Factors TNF Superfamily Ligands TNF-alpha

10
HY-10966 SB-590885
SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer.
Raf   Apoptosis  
Neurological, Eye or Ear Disease   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Obesity  
9
HY-15246 Tovorafenib
Tovorafenib (TAK-580, MLN 2480) is an orally active and selective inhibitor of pan-Raf kinase. Tovorafenib can be used for the study of glioma.
Raf  
Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Obesity  
8
HY-P9919 Durvalumab
Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody. Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.

Species: Human

PD-1/PD-L1  
Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
7
HY-N9933 Tauro-β-muricholic acid
Tauro-β-muricholic acid (TβMCA) is an orally active trihydroxylated bile acid and a competitive, reversible FXR antagonist (IC50=40 μM). Tauro-β-muricholic acid inhibits bile acid-induced hepatocyte apoptosis by maintaining mitochondrial membrane potential, while simultaneously inhibiting intestinal FXR signaling, affecting bile acid synthesis, hepatic lipid metabolism, and insulin sensitivity. Accumulation of tauro-β-muricholic acid disrupts metabolic homeostasis, promoting cancer stem cell proliferation and tumor progression. The mechanisms of tauro-β-muricholic acid involve two aspects: first, inhibiting the translocation of the pro-apoptotic protein Bax to mitochondria and maintaining mitochondrial membrane potential (MMP); and second, blocking the FXR signaling pathway to regulate bile acid metabolism, reduce serum ceramide production, and downregulate the hepatic SREBP1C/CIDEA pathway. Tauro-β-muricholic acid possesses anti-hepatocyte apoptosis, bile acid homeostasis regulation, and liver fat accumulation reduction properties, and also functions as a biomarker, making it useful in the study of diseases such as bile acid metabolism disorders, non-alcoholic fatty liver disease, colorectal cancer, and liver fibrosis.

Source: rat

FXR   Apoptosis  
Cancer   Digestive System Disease   Neurodegenerative Disease   Digestive System Inflammation   Obesity  
6
HY-W017443 L-Asparagine monohydrate
L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation  
5
HY-130208 Thiodigalactoside
Thiodigalactoside (TDG) is an orally active and potent galectin (GAL) inhibitor with Kd values of 24 μM, 49 μM for GAL1 and GAL3, respectively. Thiodigalactoside, a non-metabolizable disaccharide, has anti-inflammatory and anti-cancer activity. Thiodigalactoside dramatically reduces body weight gain in diet-induced obese rats.
Galectin  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
5
HY-N0667 L-Asparagine
L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Digestive System Disease   Digestive System Inflammation   SARS-CoV-2 Infection  
5
HY-K1011A 3-Color Prestained Protein Marker (10-180 kDa)

MCE 3-Color Prestained Protein Marker (10-180 kDa) consists of 10 prestained recombinant proteins with an apparent molecular weight range of 10–180 kDa. This marker enables real-time monitoring of protein migration during SDS-PAGE and facilitates evaluation of protein transfer efficiency. The 250 μL is defined as the base specification. All larger sizes correspond to incremental volumes of this base.

Protein Biology Protein Electrophoresis & WB Protein Marker

4
HY-Y0344J Sodium chloride, for molecular biology
Sodium chloride is an orally active salt. Sodium chloride induces the expression of ATP1A1. Sodium chloride induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells.
Biochemical Assay Reagents   Na+/K+ ATPase   Interleukin Related  
Autoimmune Disease   Small Cell Lung Cancer  
3
HY-P99575 Tarlatamab
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

Species: Human

Notch  
Inflammation or Immune System Disease   Respiratory Disease   Small Cell Lung Cancer  
3
HY-B0459 Scopine
Scopine is a metabolite of Scopolamine (HY-N0296) and brain-targeting compound. Scopine significantly increases the brain exposure of Chlorambucil (HY-13593) and enhances its anti-glioma activity. Scopine can be used in targeted therapy research for brain gliomas.
Drug Metabolite  
Cancer   Neurological, Eye or Ear Disease  
2
HY-113011 Maltotriose
Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
Endogenous Metabolite  
2
HY-K6007 Basement Membrane Matrix for Organoid Culture

MCE Basement Membrane Matrix for Organoid Culture is primarily composed of natural basement membrane matrix extracted from mouse tumors. This product is mainly used for organoid culture.

Cell Biology 3D Cell Culture Basement Membrane Matrix

2
HY-K6008 Basement Membrane Matrix HC

MCE High-Concentration Basement Membrane Matrix (Phenol Red-Free) is primarily composed of natural basement membrane matrix extracted from mouse tumors. It is rich in extracellular matrix components and various naturally occurring growth factors, and is mainly used for the establishment of animal models and 3D tumor models.

Cell Biology 3D Cell Culture Basement Membrane Matrix

2
HY-K6011 Tumor Tissue Dissociation Solution

MCE Tumor Tissue Dissociation Solution is able to gently and efficiently dissociate tumor tissue samples into cell suspensions or cell aggregates, which can then be used for the subsequent construction of tumor organoids.

Cell Biology 3D Cell Culture Organoid Research

2
HY-NP181 Testosterone/BSA
Testosterone/BSA, a conjugate of Testosterone (HY-113415) and bovine serum albumin (BSA), acts as a nuclear transporter and cytoplasmic accumulator. Testosterone/BSA can enter the nuclei of rat testicular spermatocytes, spermatids and rat liver endothelial cells, while the antigenicity of BSA remains intact. Testosterone/BSA accumulates in the cytoplasm of rat hepatocytes in granular form. Testosterone/BSA can be used to investigate the membrane-initiated or non-genomic activities of steroid hormones.
Biochemical Assay Reagents  
1
HY-N0667S5 L-Asparagine-d3 hydrate
L-Asparagine-d3 hydrate is the deuterium labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
1
HY-W089353 8-Phenyl-BODIPY 505/515
8-Phenyl-BODIPY 505/515 is a molecular rotor based on the BODIPY scaffold, specifically used as a microviscosity probe. The working principle of 8-Phenyl-BODIPY 505/515 is based on the restriction of molecular motion by viscosity: in a high-viscosity environment, the rotational freedom of its chemical bonds is inhibited, which leads to a significant extension of fluorescence lifetime. This property makes 8-Phenyl-BODIPY 505/515 an effective tool for monitoring changes in the viscosity of intracellular microenvironments via fluorescence lifetime imaging (FLIM) technology.
MOFs   Fluorescent Dye  
1
HY-13912G IWP-2 (GMP)
IWP-2 (GMP) is >IWP-2 (HY-13912) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and blocks Wnt ligand palmitoylation.
Wnt  
Cancer  
1
HY-Y0319B1 Potassium acetate, for molecular biology
Potassium acetate, for molecular biology is an acetate salt commonly used as a deicing agent, food preservative and potassium source. Potassium acetate, for molecular biology can serve as an activator for preparing waste tea-based activated carbon, and is applied to the adsorption of Acid Blue 25 dye.
Environmental Pollutants   Biochemical Assay Reagents  
1
HY-113289 Brassicasterol
Brassicasterol is a metabolite of Ergosterol and has cardiovascular protective effects. Brassicasterol exerts anticancer effects in prostate cancer through dual targeting of AKT and androgen receptor signaling pathways. Brassicasterol inhibits HSV-1 (IC50=1.2 μM) and Mycobacterium tuberculosis. Brassicasterol also inhibits sterol δ 24-reductase, slowing the progression of atherosclerosis. Brassicasterol is also a cerebrospinal fluid biomarker for Alzheimer's disease.

Source: Hippocampus abdominalis

Akt   Drug Metabolite   Bacterial   Androgen Receptor   HSV  
Prostate Cancer   HSV Infection   Alzheimer's Disease   Atherosclerosis  
1
HY-N0791 Tectoridin
Tectoridin is a isoflavone isolated from Maackia amurensis. Tectoridin is a phytoestrogen and activates estrogen and thyroid hormone receptors. Tectoridin exerts the estrogenic effects via ER-dependent genomic pathway and GPR30-dependent nongenomic pathway.
Estrogen Receptor/ERR  
Cancer  
1
HY-B2243B Anhydrous sodium dihydrogen phosphate, for molecular biology
Anhydrous sodium dihydrogen phosphate, for molecular biology is an inorganic salt compound that can be used as a buffer and nutritional supplement. Anhydrous sodium dihydrogen phosphate, for molecular biology can be used in molecular biology experiments.
Environmental Pollutants   Biochemical Assay Reagents  
1
HY-113100 N-Acetylputrescine hydrochloride
N-Acetylputrescine hydrochloride is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine hydrochloride may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine hydrochloride can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine hydrochloride can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD).
Endogenous Metabolite  
Lung Cancer   Parkinson's Disease  
1
HY-N0667S2 L-Asparagine-15N2 monohydrate
L-Asparagine-15N2 monohydrate is the 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
1
HY-113217 Cholesteryl oleate
Cholesteryl oleate is an ester compound formed from Cholesterol (HY-N0322) and Oleic acid (HY-N1446), which is involved in lipid transport, storage and cell membrane formation in living organisms. Cholesteryl oleate may serve as a potential biomarker for prostate cancer. Cholesteryl oleate can also prepare cationic solid lipid nanoparticles (SLNs) for efficient gene silencing.
Liposome   Endogenous Metabolite  
Metabolic or Endocrine Disease   Prostate Cancer  
1
HY-D1553 BODIPY-C12
BODIPY-C12 is a boron-dipyrromethene derivative containing a lipophilic tail (excitation 490 nm). BODIPY-C12 is a hydrophobic molecular and sensitivity to the surrounding environment and can be used to quantify viscosity, critical micelle concentration, and critical micelle temperature.
Fluorescent Dye  
1
HY-147041 Selvigaltin
Selvigaltin (GB1211) is an orally active galectin-3 small molecule inhibitor with an IC50 value of 12 nM in rabbits, showing anti-tumor activity. Selvigaltin decreases galectin-3 levels in the liver and reduces biomarkers of liver function (AST, ALT, bilirubin), inflammation (cells foci) and fibrosis (PSR, SHG), as well as decreasing the mRNA and protein expression of several key inflammation and fibrosis biomarkers (IL6, TGFβ3, SNAI2, collagen). Selvigaltin restores T-cell activity and induces less tumors and metastasis.
Galectin  
Inflammation or Immune System Disease  
1
HY-W342604 N-Acetylputrescine
N-Acetylputrescine is a polyamine metabolite that regulates cell proliferation and signal transduction mainly by participating in polyamine acetylation modification. N-Acetylputrescine may reduce the positive charge of polyamines, affect protein-nucleic acid interactions, and promote cell growth. The concentration changes of N-Acetylputrescine can help disease diagnosis (such as early screening and efficacy evaluation of lung cancer) and microbial cell wall structure research. N-Acetylputrescine can be used as a potential biomarker for the progression of squamous cell carcinoma of the lung (SCCL) and Parkinson's disease (PD).
Endogenous Metabolite  
Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Parkinson's Disease  
1
HY-P99144A Anti-Mouse PD-1 Antibody (S-5001)
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting PD-1, blocking the PD-1/PD-L1 immune checkpoint axis through competitive binding to PD-1. Anti-Mouse PD-1 Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy.

Species: Mouse

PD-1/PD-L1  
Cancer Immunology   Immunotherapy for Melanoma   Squamous Cell Carcinoma  
1
HY-109521A Manganese chloride tetrahydrate, molecular biology grade,≥99.0% (KT)
Manganese chloride (tetrahydrate), molecular biology grade,≥99.0% (KT) is an orally active and a blood-brain barrier penetrant compound. It affects the activities of multiple enzymes in cells, such as regulating the activities of histone acetyltransferase (HAT) and histone deacetylase (HDAC), thereby affecting gene expression. It has multiple activities such as neurotoxicity, embryotoxicity, and reproductive toxicity. It is currently mainly used in neurodegenerative diseases and toxicology research.
Biochemical Assay Reagents   Histone Acetyltransferase   HDAC  
Neurological, Eye or Ear Disease  
1
HY-W019981B Magnesium chloride hexahydrate, for molecular biology
Magnesium chloride hexahydrate (MgCl2 hexahydrate), for molecular biology is the hexahydrate form of magnesium dichloride. Magnesium chloride hexahydrate can be used as a source of magnesium ion and a co-foactor for many enzymes. Magnesium chloride hexahydrate increases the activity of Ca2+ ATPase.
Calcium Channel   Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
1
HY-P99675 Ivonescimab
Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Species: Human

PD-1/PD-L1   VEGFR  
Respiratory Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
1
HY-P72257 Cellular tumor antigen P53/TP53, Human (His-SUMO)
The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His-SUMO) is the recombinant human-derived Cellular tumor antigen P53/TP53, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Human; Source: E. coli

1
HY-106263A Tyroserleutide TFA
Tyroserleutide TFA, isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.
Others  
/
HY-106263 Tyroserleutide
Tyroserleutide (YSL), isolated from the degradation products of porcine spleen, is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo.
Others  
/
HY-50751G Linifanib (GMP)
Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells.
VEGFR   PDGFR  
/
HY-10407G SU 5402 (GMP)
SU 5402 (GMP) is SU 5402 (HY-10407) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.
VEGFR   EGFR   PDGFR  
Cancer  
/
HY-100966S BD-1008-d5 dihydrobromide
BD-1008-d5 dihydrobromide is the deuterium labeled BD-1008 dihydrobromide (HY-100966). BD-1008 dihydrobromide is a nonselective σ receptor antagonist with Kis against σ1 receptor and σ2 receptor of 2 nM and 8 nM. The BD-1008 dihydrobromide has an extremely low affinity for the D2 receptor (Ki = 1112 nM) and dopamine transporter (DAT) (Ki > 10,000 nM). BD-1008 dihydrobromide significantly antagonizes dopamine release in the shell region of the nucleus accumbens via the σ₂ receptor. BD-1008 dihydrobromide blocks the self-administration behavior of σ agonists.BD-1008 dihydrobromide can be used for the study of addiction therapy that target the σ receptor.
Isotope-Labeled Compounds   Sigma Receptor  
Neurological, Eye or Ear Disease  
/
HY-D2281 FAP Ligand 2
FAP Ligand 2, a FAPI-46 derivative, is a specific fibroblast activation protein (FAP)-targeted tracer. FAP Ligand 2 exhibits good tumor uptake and acts as a promising molecular tracer for FAP tumor imaging.
FAP  
/
HY-162051 CYP1B1-IN-6
CYP1B1-IN-6 (compound 19) is a fluorescence molecular probes which inhibits CYP1B1 activity. CYP1B1-IN-6 can identify tumor sites in fluorescence imaging and photoacoustic imaging modes.
Cytochrome P450  
/
HY-10227G Bortezomib (GMP)
Bortezomib (GMP) (PS-341 (GMP)) is Bortezomib (HY-10227) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM). Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs).
Proteasome   NF-κB   Apoptosis   Autophagy   TREM receptor  
Cancer  
/
HY-D1045A Dabcyl acid sodium
Dabcyl acid sodium (DABCYL sodium) is a nonfluorescent chromophore and a quencher. Dabcyl acid sodium can be used as molecular beacon nucleic acid probes to recognize and report the presence of specific nucleic acids in homogeneous solutions.
Fluorescent Dye  
/
HY-P992155 Arevirumab
Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever.

Species: Lassa virus

Arenavirus  
Viral Infection  
/
HY-158498 FA2 glycan (G0F)
FA2 glycan (G0F) (FA2 N-linked oligosaccharide; F(6)A2 glycan) is a core-fucosylated biantennary N-linked oligosaccharide that serves as a prostate cancer biomarker. The level of FA2 glycan (G0F) is higher in prostate cancer than in benign prostatic hyperplasia, and it is further elevated in advanced prostate cancer with a Gleason score ≥8 compared with both benign prostatic hyperplasia and low-/intermediate-risk prostate cancer. FA2 glycan (G0F) can be used in prostate cancer research.
Biochemical Assay Reagents  
Prostate Cancer  
/
HY-W583868S 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE-d62
1-Palmitoyl-2-oleoyl-sn-glycero-3-PE-d62 (1,2-POPE-d62) is the deuterium labeled 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE (1,2-POPE; 16:0-18:1 PE) is a phosphatidylethanolamine (PE) lipid. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can induce lipid bilayer to form a hexagonal phase (HII) structure in an acidic environment and promote membrane fusion. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can enhance the endosomal escape ability of lipid nanoparticles (LNPs) and improve the cellular delivery efficiency of nucleic acid drugs such as mRNA. 1-Palmitoyl-2-oleoyl-sn-glycero-3-PE can be used for LNP carrier targeting of gene therapy and mRNA vaccines.
Isotope-Labeled Compounds  
/
HY-P10065 RKLLW-NH2
RKLLW-NH2 is a Cathepsin L inhibitor.
Cathepsin  
Inflammation or Immune System Disease  
/
HY-N16775 Gylongiposide I
Gylongiposide I is a selective inhibitor against the enterovirus EV71 with an EC50 of 1.53 μM. Gylongiposide I exerts antiviral activity by reducing viral protein VP1 expression and viral genomic RNA levels. Gylongiposide I can be used in the development of anti-EV71 drugs related to hand, foot and mouth disease.
Enterovirus  
Viral Infection  
/
HY-P991270 MT204
MT204 is a humanized IgG1 antibody inhibitor targeting IL-2 of human and rhesus monkey origin. MT204 prevents soluble IL-2 from binding to intermediate-affinity IL-2 receptors and blocks CD25-bound IL-2 on high-affinity IL-2 receptors. MT204 has potently anti-proliferative activity with NKL cells and primary NK cells. MT204 has good tolerability and potent immunosuppressive activity in allogeneic skin graft model of rhesus monkey, promising for immunosuppressive and anti-proliferative therapy.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease  
/
HY-D3310 Fluorescein-12-dGTP
Fluorescein-12-dGTP is a fluorescein-labeled deoxyguanosine triphosphate. Fluorescein-12-dGTP incorporates into complementary allele-specific primers at SNP sites, enabling FRET with cationic conjugated polymer PFP via DNA-PFP electrostatic interactions. Fluorescein-12-dGTP incorporates into G-allele-specific primers for homozygous G/G SNP genotypes to enable genotype discrimination. Fluorescein-12-dGTP serves as a fluorescently labeled nucleotide for homogeneous solution-based SNP and FRET genotyping assays (Ex/Em = 498/517 nm).
Fluorescent Dye  
/
HY-P991406 MK-1248
MK-1248 is a human IgG4 monoclonal antibody (mAb) targeting TNFSF18. MK-1248 enhances the proliferative response of tumor-infiltrating lymphocytes to anti-CD3 stimulation and promotes the production of anti-tumor-associated regulatory cytokines. MK-1248 can be used in solid tumors research.

Species: Human

TNF Receptor  
Cancer  
/
HY-P11739 ZD2 peptide
ZD2 peptide is an EDB-FN-binding peptide with a Kd value of 11 μM. ZD2 peptide binds specifically to the EDB protein fragment of extradomain B fibronectin, a tumor microenvironment biomarker. ZD2 peptide can be conjugated to imaging agents. ZD2 peptide can be used for the research of cancer.
Biochemical Assay Reagents  
Cancer  
/
HY-114346A BODIPY FL EDA free base
ODIPY FL EDA free base is an amine-based, green fluorescent probe. The R-NH2 of ODIPY FL EDA free base can be coupled with aldehydes or ketones to form reversible Schiff base products. Convert to stable amine derivatives using reducing agents such as sodium borohydride or sodium cyanoborohydride. ODIPY FL EDA free base can be used to detect modified or normal deoxynucleotides and demonstrate DNA damage and genomic DNA methylation.
Fluorescent Dye  
/
HY-136972A GB-1a
GB-1a (Biflavanone GB-1a) is a biflavanone HIV-1 reverse transcriptase inhibitor (IC50=236 μM), with an EC50 of 38.0 μM for HIV-1 replication. GB-1a can block the conversion of HIV-1 genomic RNA to DNA and can be used in research related to AIDS (HIV-1 infection). GB-1a can be naturally extracted from the heartwood of Garcinia multiflora Champ.
HIV   Reverse Transcriptase  
HIV Infection  
/
HY-P10541 HSP70/DnaK substrate peptide
HSP70/DnaK substrate peptide is a short peptide that the HSP70/DnaK molecular chaperone can bind and act on. HSP70/DnaK substrate peptide can be used to study the mechanism of action of HSP70/DnaK in molecular chaperone function.
HSP  
/
HY-P992344 DNP002
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001).

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-175323 NOTA-IMB-RGD
NOTA-IMB-RGD is a dual molecular probe targeting integrin αvβ3 and programmed death ligand-1 (PD-L1). NOTA-IMB-RGD blocks the PD-1/PD-L1 signaling pathway and integrin αvβ3-overexpressing tumor vasculature. NOTA-IMB-RGD is promising for research of solid tumors co-expressing PD-L1 and αvβ3 (e.g., glioma, breast cancer).
Integrin   PD-1/PD-L1  
Cancer  
/
HY-N12656 Versipelostatin
Versipelostatin is a GRP78/Bip molecular chaperone down-regulator and can be isolated from the culture broth of Streptomyces versipellis 4083-SVS6.

Source: Streptomyces versipellis 4083-SVS6

HSP  
Cancer  
/
HY-W008449S2 1-Methylxanthine-d3
1-Methylxanthine-d3 is deuterated labeled 1-Methylxanthine (HY-W008449). 1-Methylxanthine, a caffeine derivative, is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP). 1-Methylxanthine enhances the radiosensitivity of tumor cells.
Drug Metabolite   Endogenous Metabolite   Isotope-Labeled Compounds  
/
HY-P0233AS Melittin-13C18,15N3 TFA
Melittin-13C18,15N3 TFA is the 15N- and 13C-labeled Melittin TFA (HY-P0233A). Melittin TFA is a PLA2 activator, stimulates the activity of the low molecular weight PLA2, while it does not the increase activity of the high molecular weight PLA2.
Isotope-Labeled Compounds   Phospholipase  
Cancer   Infection  
/
HY-P10907 Zaloganan
Zaloganan exhibits board-spectrum antibacterial activity through disruption of bacterial membranes.
Bacterial  
/
HY-N15588 Smyrindiol
Smyrindiol is a compound found in Dorstenia turbinate. Smyrindiol exerts anti-inflammatory and antimicrobial activities by inhibiting the secretion of tumor-associated proteases (MMP-2). Smyrindiol can be used in the study of brain tumors such as glioblastoma.
MMP  
Cancer  
/
HY-P991210 Efzimfotase alfa
Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP). Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP). Efzimfotase alfa is promising for research of hypophosphatasia (HPP).
Phosphatase  
Blood or Cardio-cerebrovascular Disease  
/
HY-P4089 REA
REA is a homing peptide that targets pre-cancerous tumor lymphatic vessels. REA homes to lymphatic vessels at the pre-cancerous tumor stage, but does not recognize tumor lymphatic vessels. REA can be used in pre-cancerous tumor research.
Others  
Cancer  
/
HY-P990038 Eurestobart
Eurestobart (ES002023) is a recombinant human IgG1 antibody against CD39. Eurestobart restores antitumor immunity by stabilizing the pro-inflammatory extracellular ATP (eATP) and interfering with synthesis of the immunosuppressive adenosine within the tumor microenvironment (TME). Eurestobart is used in the research of locally advanced and metastatic solid tumors.

Species: Human

NTPDase  
Neurological, Eye or Ear Disease  
/
HY-P3118 Bz-IEGR-pNA acetate
Bz-IEGR-pNA acetate is a trypsin substrate that can be hydrolyzed by prostate kinase release enzyme-related peptide KLKs.
Biochemical Assay Reagents  
/
HY-P4091A LSD acetate
LSD acetate is a peptide. LSD acetate can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD acetate can reduce the number of tumor lymphatics. LSD acetate can be used in the research of targeted therapy and diagnosis of tumor lymphatics.
Biochemical Assay Reagents  
Cancer  
/
HY-15233G Letermovir (GMP)
Letermovir (GMP) is the GMP grade of Letermovir (HY-15233). GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Letermovir (GMP) is an orally active CMV inhibitor. Letermovir (GMP) targets the CMV terminase complex rather than CMV DNA polymerase and exerts its antiviral activity. Letermovir (GMP) can be used in the study of CMV infection.
CMV  
Cytomegalovirus Infection  
/
HY-10321G PD173074 (GMP)
PD173074 GMP is PD173074 (HY-10321) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. PD173074 is an orally active FGFR inhibitor that targets the transphosphorylation of FGFR1 and FGFR2 and blocks the FGF signaling pathway. By reducing the phosphorylation level of SMAD2 and altering the expression of Nodal/Activin target genes, PD173074 eliminates endothelial differentiation potential, thereby inhibiting the formation of capillary-like structures. PD173074 blocks the proliferation and colony formation of tumor cells and increases intratumoral cell apoptosis. PD173074 successfully reverses FGF-2-induced chemoresistance to enhance the effect of cisplatin (HY-17394) in small cell lung cancer models. PD173074 can be applied to research related to critical limb ischemia and small cell lung cancer.
FGFR   TGF-beta/Smad  
Small Cell Lung Cancer  
/
HY-19980G Eprenetapopt (GMP)
Eprenetapopt (GMP) (APR-246(GMP)) is Eprenetapopt (HY-19980) in GMP grade. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance.
MDM-2/p53   Ferroptosis   Autophagy   Apoptosis  
Non-Small Cell Lung Cancer  
/
HY-12238G IWR-1 (GMP)
IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis.
Organoid   Wnt  
Inflammation or Immune System Disease  
/
HY-P11334 Cyanostatin B
Cyanostatin B, a cyanobacterial lipopeptide, is a leucine aminopeptidase M (LAP) inhibitor (IC50 = 12 ng/mL). Cyanostatin B is a weak inhibitor of protein phosphatase (PP2A) and also exhibits weak inhibitory activity against angiotensin-converting enzyme (ACE), with an IC50 value of 130 μg/mL. Cyanostatin B demonstrates both cytotoxic and genotoxic effects on human hepatocytes, although non-toxic to Artemia salina. Cyanostatin B inhibits the proliferation of HepG2 cells, induces DNA single-strand breaks, and causes genomic instability..
Aminopeptidase   Phosphatase   Angiotensin-converting Enzyme (ACE)   DNA/RNA Synthesis  
Cancer  
/
HY-N0667S7 L-Asparagine-13C4,15N2
L-Asparagine-13C4,15N2 ((-)-Asparagine-13C4,15N2) is the 13C and 15N-labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Inflammation or Immune System Disease  
/
HY-159771 FAP6-19
FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
FAP  
Cancer  
/
HY-Y1309S 1-Naphthol-d8
1-Naphthol-d8 is the deuterium labeled 1-Naphthol. 1-naphthol is an excited state proton transfer (ESPT) fluorescent molecular probe.
Endogenous Metabolite  
/
HY-P990873 Anti-BRCA1 Antibody (BR64)
Anti-BRCA1 Antibody (BR64) is a kind of mouse IgG1 κ chimeric antibody, targeting to human BRCA1. Anti-BRCA1 Antibody (BR64) reacts with BRCA1 (Breast cancer susceptibility gene 1) involved in tumor suppression, transcription, genomic stability, DNA repair and recombination. Anti-BRCA1 Antibody (BR64) can be used for the detections of immunofluorescence, western blot, and immunoprecipitation in cancer, such as breast and ovarian cancer.

Species: Human

DNA/RNA Synthesis  
Cancer  
/
HY-P991930 ARX305 Antibody
ARX305 Antibody is a high-affinity, humanized anti-CD70 antibody. ARX305 Antibody forms an antibody-drug conjugate (ADC) (ARX305) with the potent microtubule inhibitor PEG4-aminooxy-MMAF (AS269) (HY-128968). As a targeting component, ARX305 Antibody mediates the binding and internalization of ARX305 to CD70-positive tumor cells, whereas the unconjugated ARX305 Antibody exhibits only weak anti-tumor activity in various xenograft and disseminated tumor models. ARX305 Antibody can be used in the research of a variety of solid tumors and hematological malignancies.

Species: Human

ADC Antibodies   TNF Receptor  
Cancer  
/
HY-D1609 BODIPY FL Verapamil hydrochloride
BODIPY FL Verapamil hydrochloride is a fluorescent dye, it can be used as a molecular probe to label tissues and cells. BODIPY FL Verapamil hydrochloride is a substrate for both ABCB1 and ABCC1.
Fluorescent Dye  
/
HY-P4138 Antennapedia Peptide FAM-labeled
Antennapedia Peptide FAM-labeled is a fluorophore labeled peptide. Antennapedia Peptide FAM-labeled also can be used for the research of cancer as a molecular probe.
Fluorescent Dye  
/
HY-P3707 Tumor targeted pro-apoptotic peptide
Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice.
Apoptosis  
/
HY-P991384 DX-2240
DX-2240 is a human monoclonal antibody (mAb) targeting TIE1. DX-2240 inhibits tumor growth and sensitizes tumor vasculature to anti-angiogenic agents (VEGF pathway inhibitors).

Species: Human

Tie  
Cancer  
/
HY-P992465 SIWA318H
SIWA318H is an adbanvced glycation end product (AGE) specific antibody. SIWA318H selectively binds to advanced glycation end product biomarkers, human FcγRIIIa, and pancreatic cancer cells, and cancer-associated fibroblasts. SIWA318H suppresses tumor growth in mouse PSN1 xenografts. SIWA318H can be used for the research of pancreatic cancer.

Species: Human

Fc Receptor (FcR)  
Pancreatic Cancer  
/
HY-E70188 N-Acetylgalactosamine-6-Sulfatase
N-Acetylgalactosamine-6-Sulfatase (GALNS) is a potential general biomarker for multiple malignancies (such as lung cancer, breast cancer, head and neck cancer, etc.). N-Acetylgalactosamine-6-Sulfatase deficiency causes mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. N-Acetylgalactosamine-6-Sulfatase can be used in MPS IVA as well as cancer research.
Biochemical Assay Reagents  
/
HY-N16733 Deacetyltanghinin
Deacetyltanghinin is a selective inhibitor targeting Na+/K+ ATPase, acting through non-covalent binding but is highly cardiotoxic. Deacetyltanghinin inhibits Na+/K+ ATPase activity, induces cancer cell apoptosis (involving caspase pathway activation), and at the same time affect the TXA2-PGI2 balance in the rabbit heart. Deacetyltanghinin has significant anti-cancer activity and is mainly used in the research field of targeted therapy of malignant tumors such as breast cancer and lung cancer. At the same time, attention should be paid to the regulation of its cardiotoxicity.
Na+/K+ ATPase   Prostaglandin Receptor   Caspase   Apoptosis  
Lung Cancer   Breast Cancer  
/
HY-P992519 PF-06940434
PF-06940434 (ADWA-11) is a monoclonal antibody targeting integrin αvβ8. PF-06940434 inhibits αvβ8-mediated TGF-β activation. PF-06940434 increases the accumulation of tumor-infiltrating CD8+ T cells and upregulates the expression of granzyme B and TNF-γ. PF-06940434 blocks the inhibitory effect of CD4+CD25+ T cells on the cytotoxic activity of tumor CD8+ T cells. PF-06940434 enhances the anti-tumor efficacy of combination therapies with other immunomodulators or radiotherapy and induces long-term anti-tumor immunity. PF-06940434 can be used in the research of squamous cell carcinoma, breast cancer, colon cancer, and prostate adenocarcinoma.
Integrin   TNF Receptor   TGF-β Receptor  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Squamous Cell Carcinoma  
/
HY-D2620 CAR-2
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC50 of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models.
Photosensitizer   Reactive Oxygen Species (ROS)   Ferroptosis  
/
HY-129331 Neothramycin A
Neothramycin A is an antibiotic, which can be isolated from Streptomyces. Neothramycin A exhibits board spectrum antimicrobial activity, inhibits Staphylococcus aureus, Klebsiella pneumoniae, Escherichia coli W677, and Saccharomyces cerevisia with MIC of 25-50 μg/mL. Neothramycin A exhibits antitumor efficacy against leukemia in mouse models.

Source: Streptomyces No. MC916-C4

Antibiotic   Bacterial   Fungal  
Cancer   Infection  
/
HY-P1704 Cyclosporin E
Cyclosporin E (11-Demethylcyclosporin A) is a cyclic oligopeptide that can be isolated from fungi such as TTrichoderma polysporum and other imperfect fungi. Cyclosporin E belongs to the Cyclosporins family. Cyclosporin E can be used for studying the structure-activity relationships and molecular dynamic properties of cyclosporin compounds. As a structural control compound, Cyclosporin E holds significant research value in the fields of medicinal chemistry and biophysics.

Source: Trichoderma polysporum

Biochemical Assay Reagents  
Infection  
/
HY-D2510 Cy3-PEG2000-SH
Cy3-PEG2000-SH (Cy3-PEG-Thiol) is a near infrared fluorescent labeling reagent that combines Cy3 fluorescent dye, polyethylene glycol (PEG) and sulfhydryl (SH) polyethylene glycol derivatives, and is suitable for molecular coupling. Cy3-PEG2000-SH is absorbed at 550nm and has high solubility and end-group substitution rate.
Fluorescent Dye  
Cancer  
/
HY-W011425A NTPO trisodium
NTPO trisodium is a DNA damage inducer, causing genomic DNA damage and fragmentation, activating ATR-mediated cell cycle checkpoints. The DNA damaging effects of NTPO trisodium are abrogated by base excision repair (BER) but not nucleotide excision repair (NER).
Others  
Cancer  
/
HY-113011R Maltotriose (Standard)
Maltotriose (Standard) is the analytical standard of Maltotriose (HY-13011). This product is intended for research and analytical applications. Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
Reference Standards   Endogenous Metabolite  
/
HY-N6663R 3-Carene (Standard)
3-Carene (Standard) is the analytical standard of 3-Carene (HY-N6663). This product is intended for research and analytical applications. 3-Carene is an orally active TCA cycle enzyme inhibitor. 3-Carene inhibits succinate dehydrogenase and malate dehydrogenase as well as pyruvate kinase, disrupting energy metabolism. 3-Carene disrupts cell wall and cell membrane integrity, leading to potassium ion leakage, protein leakage, membrane depolarization, ATP depletion, morphological disruption, and cell lysis. 3-Carene interferes with amino acid metabolism, pantothenate and CoA biosynthesis, purine and pyrimidine metabolism, and aminoacyl-tRNA biosynthesis. 3-Carene enhances GABA receptor-mediated synaptic responses. 3-Carene can be used in research on bacterial infections, inflammation, anxiety, and sleep disorders.
Reference Standards   Mitochondrial Metabolism   Bacterial   GABA Receptor   Succinate Dehydrogenase   Malate Dehydrogenase (MDH)   Pyruvate Kinase  
Bacterial Infection   Anxiety or Fear-Related Disease   Sleep-Wake Disorder   Rheumatoid Arthritis  
/
HY-D2513 Cy3-PEG10000-SH
Cy3-PEG10000-SH (Cy3-PEG-Thiol) is a near infrared fluorescent labeling reagent that combines Cy3 fluorescent dye, polyethylene glycol (PEG) and sulfhydryl (SH) polyethylene glycol derivatives, and is suitable for molecular coupling. Cy3-PEG10000-SH is absorbed at 550nm and has high solubility and end-group substitution rate.
Fluorescent Dye  
Cancer  
/
HY-136177R Tris(2,4-di-tert-butylphenyl)phosphate (Standard)
Tris(2,4-di-tert-butylphenyl)phosphate (Standard) is the analytical standard of Tris(2,4-di-tert-butylphenyl)phosphate. This product is intended for research and analytical applications. Tris(2,4-di-tert-butylphenyl)phosphate is an active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory Phospholipase A2 (sPLA2) through molecular docking.
Reference Standards   Phospholipase  
Inflammation or Immune System Disease  
/
HY-100679S Pirlindole-d4
Pirlindole-d4 is the d4-labeled Pirlindole (HY-100679). Pirlindole is an orally active, selective and reversible MAO-A inhibitor with an IC50 value of 250 nM. Pirlindole inhibits genomic replication of Enterovirus species B and D, and exhibits moderate activity against enterovirus species A. Pirlindole inhibits MAO-A-mediated monoamine metabolism, promotes adult hippocampal neurogenesis, rescues stress-induced dendritic atrophy of hippocampal granule neurons, reverses behavioral effects associated with chronic mild stress, and also possesses anticonvulsant, analgesic, local anesthetic, hypotensive, antiplatelet aggregation and antispasmodic activities. Pirlindole shows no detectable mutagenic, clastogenic or carcinogenic properties. Pirlindole can be used in research related to depression and enterovirus infections.
Isotope-Labeled Compounds   Monoamine Oxidase   Enterovirus  
Cancer   Viral Infection   Depression   Epilepsy   Pain   Platelet Disease   Muscle Relaxation and Spasm  
/
HY-149413 FHND5071
FHND5071 is a potent and selective RET kinase inhibitor, FHND5071 can exert antitumor effects by inhibiting RET autophosphorylation. FHND5071 can be used for tumor diseases research.
RET  
Cancer  
/
HY-N15176 Bisucaberin
Bisucaberin is a natural siderophore, is a DNA synthesis inhibitor. Bisucaberin shows cytostasis for tumor cells. Bisucaberin sensitizes tumor cells to macrophage-mediated cytolysis.

Source: Alteromonas haloplanktis Strain SB-1123

DNA/RNA Synthesis  
/
HY-D2511 Cy3-PEG3400-SH
Cy3-PEG3400-SH (Cy3-PEG-Thiol) is a near infrared fluorescent labeling reagent that combines Cy3 fluorescent dye, polyethylene glycol (PEG) and sulfhydryl (SH) polyethylene glycol derivatives, and is suitable for molecular coupling. Cy3-PEG3400-SH is absorbed at 550nm and has high solubility and end-group substitution rate.
Fluorescent Dye  
Cancer  
/
HY-B0109AS Dorzolamide-d3 hydrochloride
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
Carbonic Anhydrase   Isotope-Labeled Compounds  
/
HY-P991517 BI-836858
BI-836858 is a fully human anti-CD33 monoclonal antibody. BI-836858 reduces CD33+ cells via antibody-dependent cellular cytotoxicity (ADCC), blocks downstream signaling of S100A9/CD33, decreases the secretion of immunosuppressive cytokines and reactive oxygen species-induced genomic instability, and restores bone marrow hematopoietic function. BI-836858 is applicable to the research of myelodysplastic syndrome (MDS) and AML.

Species: Human

Transmembrane Glycoprotein   Reactive Oxygen Species (ROS)  
Leukemia/Lymphoma/Myeloma   Myelodysplastic Syndrome  
/
HY-W755036 Oxytetracycline-13C,d3 hydrochloride
Oxytetracycline-13C,d3 hydrochloride is the 13C- and deuterium labeled Oxytetracycline hydrochloride (HY-B0275A). Oxytetracycline hydrochloride is an antibiotic that exhibits board-spectrum antibacterial activity. Oxytetracycline hydrochloride is a protein synthesis inhibitor and prevents the binding from aminoacil-tRNA to the complex m-ribosomal RNA. Oxytetracycline hydrochloride also possesses anti-HSV-1 activity.
Isotope-Labeled Compounds   Bacterial   HSV   Antibiotic  
Bacterial Infection  
/
HY-B0338S Rimantadine-d4 hydrochloride
Rimantadine-d4 (hydrochloride) is the deuterium labeled Rimantadine hydrochloride. Rimantadine is an orally active inhibitor for M2 protein, that blocks the hydrogen ion channel activity, prevents the entry and replication of the virus, and exhibits board-spectrum antiviral activity.
Isotope-Labeled Compounds   Influenza Virus   Autophagy  
Infection  
/
HY-W777859 5-Methyl cytosine-13C,15N2 hydrochloride
5-Methyl cytosine-13C,15N2 hydrochloride (5-Methylcytosine hydrochloride-13C,15N2) is the 13C- and 15N-labeled 5-Methylcytosine hydrochloride (HY-W008091A). 5-Methylcytosine hydrochloride plays a crucial role in regulating gene expression, facilitating genomic imprinting, and suppressing transposable elements, while also being intricately linked to translational fidelity and tRNA recognition.
Isotope-Labeled Compounds   Endogenous Metabolite   DNA/RNA Synthesis  
/
HY-W048671 Fmoc-Thr(TBDMS)-OH
Fmoc-Thr(TBDMS)-OH is a Threonine derivative. Fmoc-Thr(TBDMS)-OH can be used for the preparation of sugar ligand-tethered functional nucleic acid conjugates for targeted research.
Amino Acid Derivatives  
/
HY-N0791R Tectoridin (Standard)
Tectoridin (Standard) is the analytical standard of Tectoridin. This product is intended for research and analytical applications. Tectoridin is a isoflavone isolated from Maackia amurensis. Tectoridin is a phytoestrogen and activates estrogen and thyroid hormone receptors. Tectoridin exerts the estrogenic effects via ER-dependent genomic pathway and GPR30-dependent nongenomic pathway.
Reference Standards   Estrogen Receptor/ERR  
Cancer  
/
HY-P11286 A7RC
A7RC is a multifunctional peptide used in tumor-targeted therapy, with Cysteine added to the C-terminal of the A7R peptide (sequence: ATWLPPR). A7R (HY-P1663) is a ligand of the NRP-1 receptor, regulating intracellular signal transduction related to tumor vascularization and tumor growth.
Complement System  
Cancer  
/
HY-P5107A Low molecular weight protamine acetate
Low molecular weight protamine acetate (LMWP acetate;TDSP5 acetate) is a truncated arginine-rich protamine peptide, which also acts as an antidote for heparin/low molecular weight heparin and a cell-penetrating delivery vector. Low molecular weight protamine acetate neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities. Low molecular weight protamine acetate translocates across mammalian cell membranes, delivers conjugated impermeable molecules through tumor tissues, enhances the skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine acetate retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine acetate can be used in studies related to colon cancer, skin wounds and diabetic skin wounds.
VEGFR  
Cancer  
/
HY-P991689 Girancitug
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-P4091 LSD
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics.
Biochemical Assay Reagents  
Cancer  
/
HY-P10836 DN59
DN59 is a 33 amino acid peptide that mimics the dengue virus type 2 E stem region. DN59 inhibits all four serotypes of dengue virus (IC50: 2-5 μM) as well as other flaviviruses. N59 causes the release of genomic RNA by interacting directly with viral particles. DN59 has antiviral activity.
Dengue Virus  
Infection  
/
HY-W017443S1 L-Asparagine-amide-15N monohydrate
L-Asparagine-amide-15N monohydrate is the 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P991294 MGTA-117 Antibody
MGTA-117 is a humanized monoclonal antibody targeting CD117. MGTA-117 can be used for synthesis of antibody-drug conjugate (ADC), utilizing an amanitin payload. MGTA-117 has potent anti-tumor activity and increases survival in three acute myeloid leukemia (AML) xenograft hNSG mice models (Kasumi-1, AML PDX 1 and AML PDX 2). MGTA-117 enables hematopoietic stem cell transplantation (HSCT) preprocessing in AML, myelodysplasia with excess blasts (MDS-EB) and gene therapy.

Species: Human

ADC Antibodies  
Cancer  
/
HY-P5931 Spinoxin
Spinoxin isolated from the venom of scorpion Heterometrus spinifer, is a 34-residue peptide neurotoxin cross-linked by four disulfide bridges. Spinoxin is a potent inhibitor of Kv1.3 potassium channel (IC50 = 63 nM), considering to be valid molecular targets in the diagnostics and therapy of various autoimmune disorders and cancers.
Potassium Channel  
Cancer   Inflammation or Immune System Disease  
/
HY-W587784 Norbixin
Norbixin is an orally active natural product with multiple activities such as retinal protection and oxidative stress regulation. Norbixin scavenges ROS, chelates metal ions, regulates plasmid and genomic DNA breakage, inhibits H2O2-induced mutagenesis, activates PPAR-α, modulates lipid levels, restores or regulates antioxidant enzyme activity, and alters NO levels. Norbixin prevents A2E accumulation and protects photoreceptor cells and retinal pigment epithelial cells. Norbixin is a derivative of Bixin (HY-N6884). Norbixin can be used in research related to diseases such as macular degeneration and diabetes, and also serves as a natural textile dye.
PPAR   Reactive Oxygen Species (ROS)   NO Synthase   DNA/RNA Synthesis  
Retinopathy   Type 1 Diabetes   Type 2 Diabetes  
/
HY-P99035 Naptumomab
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma.

Species: Human

Others  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Luminal Breast Cancer   Triple-Negative Breast Cancer  
/
HY-P990716 Sabestomig
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma.

Species: Human

PD-1/PD-L1   Tim3  
Inflammation or Immune System Disease  
/
HY-113110A Cysteinylglycine TFA
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) TFA is a dipeptide formed by the peptide bond connection of cysteine and glycine. Cysteinylglycine TFA is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine TFA can reduce trivalent iron to divalent iron, driving the redox cycle of iron, generating reactive oxygen species (ROS), stimulating oxidative reactions, inducing lipid peroxidation in human plasma LDL lipoproteins, and causing oxidative damage to DNA base. Cysteinylglycine TFA can be used as a biomarker to assess ischemic heart disease and breast cancer, etc.
Endogenous Metabolite   Reactive Oxygen Species (ROS)   DNA/RNA Synthesis  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P99382A Vopratelimab (Mouse IgG2a)
Vopratelimab (Mouse IgG2a) is a agonist monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy.

Species: Human

Others  
Cancer  
/
HY-W015787 2-Hydroxyphenylethanol
2-Hydroxyphenylethanol is a molecular chaperone that rescues misfolded P123S mutant pendrin, promoting translocation from the cytoplasm to the plasma membrane. 2-Hydroxyphenylethanol can be used for the research of pendred syndrome.
Chloride Channel  
Ear Disease  
/
HY-W048674 Fmoc-Ser(Ac)-OH
Fmoc-Ser(Ac)-OH (Fmoc-O-acetyl-L-serine) is a Serine derivative. Fmoc-Ser(Ac)-OH can be used for the preparation of broad-spectrum coronavirus membrane fusion inhibitor.
Amino Acid Derivatives  
Infection  
/
HY-15764G A 419259 (GMP)
A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC50s of 9 nM, <3 nM, and <3 nM, respectively.
Src   Apoptosis  
Cancer  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-P99489 Budigalimab
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors.

Species: Human

PD-1/PD-L1  
Inflammation or Immune System Disease   Non-Small Cell Lung Cancer   Triple-Negative Breast Cancer  
/
HY-P991577 DS-8895
DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with 89Zr, 111In, or 125I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo..

Species: Human

Ephrin Receptor  
Cancer  
/
HY-P2255 H3K4(Me) (1-20)
H3K4(Me) (1-20), a histone peptide. H3K4me is an intricately regulated posttranslational modification, which is broadly associated with enhancers and promoters of actively transcribed genomic loci.
Histone Demethylase  
/
HY-113144AS L-Hexanoylcarnitine-d3 chloride
L-Hexanoylcarnitine-d3 chloride is the deuterium labeled L-Hexanoylcarnitine chloride. L-Hexanoylcarnitine chloride is an acylcarnitine and also a urinary biomarker for hyperlipidemia. The expression of L-Hexanoylcarnitine chloride is upregulated in colorectal cancer cells, which is associated with metabolic pathways related to cell growth and proliferation. L-Hexanoylcarnitine chloride can be used in studies related to hyperlipidemia and stage B colorectal cancer.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease  
/
HY-121107S Chrysene-d12
Chrysene-d12 is the deuterium labeled Chrysene. Chrysene is a high molecular weight (HMW), polycyclic aromatic hydrocarbon (PAH) known for its recalcitrance and carcinogenic properties.
Isotope-Labeled Compounds  
Cancer  
/
HY-Y1097S Monomethyl phthalate-d4
Monomethyl phthalate-d4 (2-(Methoxycarbonyl)benzoic acid-d4) is the deuterium labeled Monomethyl phthalate. Monomethyl phthalate is a phthalate metabolite. Monomethyl phthalate acts as a urinary biomarker of phthalates exposure and can be used as a standard for the determination of thyroid cancer and benign nodule.
Isotope-Labeled Compounds  
Cancer  
/
HY-N6663 3-Carene
3-Carene is an orally active TCA cycle enzyme inhibitor. 3-Carene inhibits succinate dehydrogenase and malate dehydrogenase as well as pyruvate kinase, disrupting energy metabolism. 3-Carene disrupts cell wall and cell membrane integrity, leading to potassium ion leakage, protein leakage, membrane depolarization, ATP depletion, morphological disruption, and cell lysis. 3-Carene interferes with amino acid metabolism, pantothenate and CoA biosynthesis, purine and pyrimidine metabolism, and aminoacyl-tRNA biosynthesis. 3-Carene enhances GABA receptor-mediated synaptic responses. 3-Carene can be used in research on bacterial infections, inflammation, anxiety, and sleep disorders.
Mitochondrial Metabolism   Bacterial   GABA Receptor   Succinate Dehydrogenase   Malate Dehydrogenase (MDH)   Pyruvate Kinase  
Bacterial Infection   Anxiety or Fear-Related Disease   Sleep-Wake Disorder   Rheumatoid Arthritis  
/
HY-P99179 CTX-2026
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer.

Species: Human

Others  
Cancer  
/
HY-N6043 Hydroxytyrosol acetate
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields.
Free Radical Scavengers   Apoptosis   Reactive Oxygen Species (ROS)   Bacterial   SARS-CoV   Estrogen Receptor/ERR  
Bacterial Infection   Alzheimer's Disease   Atherosclerosis and Inflammation  
/
HY-P2213A GPLGIAGQ TFA
GPLGIAGQ TFA, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ TFA can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT).
MMP   Apoptosis  
Cancer  
/
HY-148979 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine
1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine (SAPE) is a fluorescent reporter that specifically binds biotin. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine produces a detectable fluorescent signal to quantify target factors. 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine can be used for the research of primary liver cancer, cervical cancer.
Fluorescent Dye  
Liver Cancer   Cervical Cancer  
/
HY-P2258 Histone H3 (1-34)
Histone H3 (1-34) is a peptide derived from human histone isotype 3.1. Histones are the main protein components of eukaryotic chromatin. Histone variants and histone modifications modulate chromatin structure, ensuring the precise operation of cellular processes associated with genomic DNA.
Histone Methyltransferase  
/
HY-12678S1 Entrectinib-d8
Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice.
Isotope-Labeled Compounds   Trk Receptor   Anaplastic lymphoma kinase (ALK)   Autophagy   ROS Kinase  
/
HY-113217S Cholesteryl oleate-d7
Cholesteryl oleate-d7 is deuterium labeled Cholesteryl oleate. Cholesteryl oleate is an ester compound formed from Cholesterol (HY-N0322) and Oleic acid (HY-N1446), which is involved in lipid transport, storage and cell membrane formation in living organisms. Cholesteryl oleate may serve as a potential biomarker for prostate cancer. Cholesteryl oleate can also prepare cationic solid lipid nanoparticles (SLNs) for efficient gene silencing.
Isotope-Labeled Compounds   Endogenous Metabolite  
/
HY-D0227ES THAM-d11 (for molecular biology)
Trometamol(Tris),for molecular biology-d11 is the deuterium labeled Trometamol(Tris),for molecular biology.
Isotope-Labeled Compounds  
/
HY-P5107 Low molecular weight protamine
Low molecular weight protamine (LMWP;TDSP5) is a truncated arginine-rich protamine peptide, as well as a heparin/low-molecular-weight heparin antidote and a cell-penetrating delivery carrier. Low molecular weight protamine neutralizes heparin-induced anticoagulant activities, including aPTT, anti-Xa and anti-IIa activities, and also neutralizes anti-Xa activity of commercially available low-molecular-weight heparin preparations. Low molecular weight protamine translocates across mammalian cell membranes, delivers conjugated impermeable molecules across tumor tissues, enhances skin permeability of conjugated epidermal growth factor, and accelerates wound healing when conjugated with epidermal growth factor. Low molecular weight protamine retains the in vitro cell proliferation activity of conjugated EGF, and also enables site-specific conjugation with peptides or proteins via genetic recombination. Low molecular weight protamine can be used in studies related to colon adenocarcinoma, skin wounds and diabetic skin wounds.
VEGFR  
Cancer  
/
HY-D1603 BODIPY FL-EDA
BODIPY FL-EDA is a widely used fluorescent dye for quantitative analysis of nucleotides. BODIPY FL-EDA is an aliphatic amine analog that can react with aldehydes and ketones. BODIPY FL-EDA can be used to detect both modified and unmodified deoxynucleotides and to determine DNA damage and genomic DNA methylation through capillary electrophoresis with laser-induced fluorescence (CE-LIF). Additionally, it can be used for quantifying intracellular ATP levels. The excitation wavelength is 500 nm, and the emission wavelength is 510 nm.
Fluorescent Dye  
/
HY-W008951 Ethylenediaminetetra(methylenephosphonic acid)
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers.
Radionuclide-Drug Conjugates (RDCs)  
Pain   Multiple Myeloma  
/
HY-W017443S L-Asparagine-13C4,15N2 monohydrate
L-Asparagine-13C4,15N2 monohydrateis the 13C-labeled and 15N-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-N0181A Lumisterol
Lumisterol (9β,10α-Ergosterol) is a photoproduct of 7-dehydrocholesterol, present in the skin, and acts as an orally active VDR non-genomic modulator and ROR inverse agonist. Lumisterol binds to the SARS-CoV-2 Mpro substrate-binding pocket and the RdRP active site, inhibiting enzyme activity. Lumisterol induces NRF2-regulated antioxidant responses, p53 phosphorylation and nuclear translocation, and intracellular free radical scavenging. Lumisterol inhibits the proliferation of epidermal keratinocytes and melanoma cells, modulates cell cycle progression, and suppresses basal and TNFα-induced NFκB transcriptional activity. Lumisterol inhibits RORγ transcriptional activity and IL-17 production. Lumisterol is used in research on UVB-induced skin damage, melanoma, psoriasis, vitamin D deficiency, and COVID-19.
Endogenous Metabolite   VD/VDR   ROR   Keap1-Nrf2   MDM-2/p53   Free Radical Scavengers   NF-κB   TNF Receptor   Interleukin Related  
Metabolic or Endocrine Disease   Melanoma   Coronavirus Infection   Skin Disease   Psoriasis  
/
HY-P2213 GPLGIAGQ
GPLGIAGQ, a MMP2-cleavable polypeptide, is used as a stimulus-sensitive linker in both liposomal and micellar nanocarriers for MMP2-triggered tumor targeting. GPLGIAGQ can be used to synthesis unique MMP2-targeted photosensitizer in photodynamic therapy (PDT).
MMP   Apoptosis  
Pancreatic Cancer   Pain   Digestive System Inflammation  
/
HY-W011258 H-Tyr-Phe-OH
H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) is an orally active inhibitor of Angiotensin converting enzyme (ACE), with an inhibiton rate of 48% at 50 μM. H-Tyr-Phe-OH can be used as an biomarker for differentiating benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH exhibits xanthine oxidase inhibition (uric acid lowering) activity and serves as regulator in IL-8 production in neutrophil-like cells.
Xanthine Oxidase   Angiotensin-converting Enzyme (ACE)  
Inflammation or Immune System Disease  
/
HY-N0667S3 L-Asparagine-13C4 monohydrate
L-Asparagine-13C4 monohydrate is the 13C-labeled L-Asparagine monohydrate (HY-W017443). L-Asparagine monohydrate is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine monohydrate can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
Isotope-Labeled Compounds   Endogenous Metabolite   Apoptosis   DNA/RNA Synthesis  
Inflammation or Immune System Disease  
/
HY-113466S 4-Hydroxynonenal-d3
4-Hydroxynonenal-d3 is the deuterium labeled 4-Hydroxynonenal. 4-Hydroxynonenal (4-HNE) is an α,β unsaturated hydroxyalkenal and an oxidative/nitrosative stress biomarker. 4-Hydroxynonenal is a substrate and an inhibitor of acetaldehyde dehydrogenase 2 (ALDH2). 4-Hydroxynonenal can modulate a number of signaling processes mainly through forming covalent adducts with nucleophilic functional groups in proteins, nucleic acids, and membrane lipids. 4-Hydroxynonenal plays an important role in cancer through mitochondria.
Isotope-Labeled Compounds   Aldehyde Dehydrogenase (ALDH)   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-185057 S-D-Lactoylglutathione
S-D-Lactoylglutathione (S-Lactylglutathione; (R)-S-Lactoylglutathione) is a multifunctional metabolic intermediate of the glyoxalase system. S-D-Lactoylglutathione activates K+ efflux in bacteria by displacing inhibitory glutathione from KefGB channels, thereby acidifying the cytoplasm. In eukaryotic cells, S-D-Lactoylglutathione mediates S-glutathionylation as a substrate of glyoxalase 2. S-D-Lactoylglutathione serves as a sensitive metabolic biomarker for neodymium nitrate neurotoxicity; when used in combination with MSCs-exo, it upregulates glutathione levels, downregulates lactate dehydrogenase and Glo2 levels, and inhibits cellular inflammatory responses and pyroptosis. S-D-Lactoylglutathione can be used in research related to prostate cancer, breast cancer, non-small cell lung cancer, sepsis-associated encephalopathy, and neurotoxicity.
Glyoxalase (GLO)   Endogenous Metabolite   Potassium Channel  
Breast Cancer   Prostate Cancer   Non-Small Cell Lung Cancer   Neurotoxic Agent  
/
HY-D0785 NBD-F
NBD-F (4-Fluoro-7-nitrobenzofurazan) is a pro-fluorescent reagent which is developed for amino acid analysis. NBD-F reacts with primary or secondary amines to produce a fluorescent product and used for analysis of amino acids and low molecular weight amines.
Fluorescent Dye  
/
HY-Y0308H Sodium phosphate dibasic, for molecular biology
Sodium phosphate dibasic (Disodium hydrogen phosphate), for molecular biology, is a type of phosphate salt that can be used in molecular biology research to prepare stable buffers free of RNase/DNase/protease.
Biochemical Assay Reagents  
/
HY-N2108 7-Ethylcamptothecin
7-Ethylcamptothecin is a derivative of Camptothecin (HY-16560) and a DNA topoisomerase I inhibitor that exhibits significant antitumor activity against tumor cells. 7-Ethylcamptothecin serves as a key precursor for the synthesis of 20 (S)-O-substituted benzoyl-7-ethylcamptothecin compounds. 7-Ethylcamptothecin is widely used in various tumor-related scientific studies.
Drug Derivative   Drug Intermediate   Topoisomerase  
Cancer  
/
HY-W012815 3-Methylcatechol
3-Methylcatechol is a phenolic derivative that can be produced by Pseudomonas putida MC2. 3-Methylcatechol can serve as a molecular building block in chemical synthesis to produce other active compounds.

Source: Rhodococcus sp. strain ZWL3NT

Biochemical Assay Reagents   Drug Intermediate  
/
HY-Y0537B Potassium chloride, for molecular biology
Potassium chloride, for molecular biology is potassium chloride that can be used in molecular biology. Potassium chloride, for molecular biology affects the stability of biological membranes by disrupting the electrostatic interactions between proteins and lipids. Potassium chloride, for molecular biology affects the solubility of myofibrillar proteins and the integrity of mitochondria. Potassium chloride, for molecular biology is commonly used in homogenization buffers and protein extraction procedures.
Environmental Pollutants   Mitochondrial Metabolism   Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-P990242 Anti-Mouse Galectin-9 Antibody (RG9-1)
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4+ and CD8+ T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia.

Species: Mouse

Galectin   TNF Receptor   IFNAR   Interleukin Related  
Inflammation or Immune System Disease   Breast Cancer  
/
HY-W251598B Sodium bicarbonate, for molecular biology
Sodium bicarbonate, for molecular biology (Sodium hydrogen carbonate for molecular biolog; Soda bicarbonate for molecular biolog) is an inorganic salt. Sodium bicarbonate can maintain the pH of the culture medium, thereby affecting the expression of inducible nitric oxide synthase (iNOS) and nitric oxide (NO) production in macrophages and reversing the acidosis of the tumor microenvironment. Sodium bicarbonate is widely used in the fields of food, cosmetics, etc. Its main uses include buffers, flavoring agents, disinfectants, pharmaceuticals, and proton gradient regulators. Sodium bicarbonate is also commonly used as an antacid to inhibit gastrointestinal diseases, neutralize gastric acid, and reduce gastric discomfort.
Bacterial   NO Synthase  
Cancer   Gastric Disease  
/
HY-W150340 β-Lactose
β-Lactose is a disaccharide commonly found in milk and dairy products. It consists of two monosaccharides, glucose and galactose, linked by β-glycosidic bonds. β-Lactose has various applications in the food industry, especially as a sweetener and bulking agent. Furthermore, it can be used as a substrate for enzymes involved in lactose metabolism and as a model compound for studying carbohydrate-protein interactions.
Galectin   Biochemical Assay Reagents  
Cancer  
/
HY-P990059 Puxitatug
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer.

Species: Human

ADC Antibodies   CD276/B7-H3  
Cancer  
/
HY-P5911 GluN1(359-378)
GluN1 (359-378) is an anti-N-methyl-D-aspartate receptor (NMDAR) peptide. GluN1 (359-378) can cross the blood-brain barrier. GluN1 (359-378) can be used to study anti-NMDAR encephalitis therapy targeting the immune system.
iGluR  
Inflammation or Immune System Disease  
/
HY-126854 N-Acetyllactosamine
N-Acetyllactosamine (N-Acetyl-D-lactosamine), a nitrogen-containing disaccharide, is a galectin-3 inhibitor, which is an important component of various oligosaccharides such as glycoproteins and sialyl Lewis X. N-Acetyllactosamine can be used as the starting material for the synthesis of various oligosaccharides. N-Acetyllactosamine has prebiotic effects.

Source: Escherichia coli strains and Corynebacterium ammoniagenes

Endogenous Metabolite   Galectin  
Cardiovascular Disease   Lung Fibrosis  
/
HY-114440 Belapectin
Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity Ki of 2.8 μM.
Galectin   Apoptosis  
/
HY-W096638A Glycerophosphocholine
Glycerophosphocholine ((S)-Glycerolphosphocholine) is an orally active metabolite that crosses the blood-brain barrier. Glycerophosphocholine acts as a precursor of acetylcholine, a specific marker for phosphatidylcholine breakdown, a major water-soluble storage form of choline, and an intermediate in phosphatidylcholine metabolism. Glycerophosphocholine is specifically elevated in the cerebrospinal fluid of Alzheimer's disease models, and it also promotes growth hormone secretion and fat oxidation. Glycerophosphocholine is also a potential biomarker for breast cancer.
Endogenous Metabolite  
Cancer   Metabolic or Endocrine Disease   Alzheimer's Disease  
/
HY-136177 Tris(2,4-di-tert-butylphenyl)phosphate
Tris(2,4-di-tert-butylphenyl)phosphate is an active compound from the leaves of Vitex negundo L. shows anti-inflammatory activity with evidence of inhibition for secretory Phospholipase A2 (sPLA2) through molecular docking.
Phospholipase  
Inflammation or Immune System Disease  
/
HY-W460407 N,N'-Dimethylhydrazine dihydrochloride
N,N'-Dimethylhydrazine (1,2-Dimethylhydrazine) dihydrochloride is a tumor inducer that induces colon tumors in rodents.
Biochemical Assay Reagents  
/
HY-150097 Recombinant Human Serum Albumin(rHSA)
Recombinant Human Serum Albumin (rHSA) is a non-glycosylated monomeric plasma protein that acts as a core factor for maintaining plasma colloid osmotic pressure. Recombinant Human Serum Albumin (rHSA) possesses multiple physiological functions including carrier, metabolic regulation, detoxification, antioxidation and enzyme mimicking. Recombinant Human Serum Albumin (rHSA) not only scavenges reactive oxygen and nitrogen species via specific residues and binds a variety of endogenous and exogenous compounds to maintain redox homeostasis, but also serves as a biomarker for multiple diseases such as cancer and inflammation. Recombinant Human Serum Albumin (rHSA) broadly supports the development of implantable materials, surgical adhesives and ligand capture, and can be used for research on critical illnesses including hypovolemia, liver failure, severe sepsis and various types of trauma resuscitation.
Biochemical Assay Reagents  
Cancer   Inflammation or Immune System Disease   Liver Failure  
/
HY-128852 N-Acetyl-D-galactosamine, 98%
N-Acetyl-D-galactosamine (GalNAc) is a terminal essential amino sugar derived from galactose and forms the antigens of blood group A in humans. N-Acetyl-D-galactosamine (GalNAc) interact with Soya bean agglutinin (SBA), hence decreasing the effects of SBA on cellular membrane permeability and tight junction protein expression in piglets. N-Acetyl-D-galactosamine (GalNAc) inhibits the hemagglutinating activity by the lectin.
Galectin   Endogenous Metabolite  
/
HY-P9969 Matuzumab
Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab.

Species: Human

EGFR  
Lung Cancer  
/
HY-113110 Cysteinylglycine
Cysteinylglycine (L-Cysteinylglycine; Cys-Gly) is a dipeptide formed by the peptide bond linkage between cysteine (Cysteine) and glycine (Glycine). Cysteinylglycine is an important metabolic intermediate in the human body, mainly derived from the degradation of glutathione (GSH). Cysteinylglycine reduces ferric iron to ferrous iron, drives the redox cycle of iron, generates reactive oxygen species (ROS), stimulates oxidative reactions, induces lipid peroxidation of human plasma LDL lipoproteins, and causes oxidative damage to DNA bases. Cysteinylglycine can be used as a biomarker to evaluate ischemic heart disease, breast cancer and other conditions.
Endogenous Metabolite   Reactive Oxygen Species (ROS)   DNA/RNA Synthesis  
Breast Cancer   Heart Disease  
/
HY-Y0849C Ammonium acetate, for molecular biology, 98%
Ammonium acetate, for molecular biology, 98% is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
Environmental Pollutants   Biochemical Assay Reagents  
/
HY-158115 NST-628
NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors.
Molecular Glues   Raf   MEK  
Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Pain   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Obesity   Rheumatoid Arthritis  
/
HY-P76124 VHL Protein, Human (His)
VHL protein is an important component of the von Hippel-Lindau ubiquitination complex and plays a key role in ubiquitination and proteasomal degradation. As a target recruitment subunit in the E3 ubiquitin ligase complex, VHL specifically recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions and regulates cellular responses to oxygen levels. VHL Protein, Human (His) is the recombinant human-derived VHL protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P73443 TNF-alpha/TNFSF2 Protein, Canine
Tumour Necrosis Factor alpha (TNF alpha) is a potent pro-inflammatory cytokine. TNF alpha binds to its receptors, mainly TNFR1 and TNFR2, and then transmits molecular signals for biological functions such as inflammation and cell death. TNF alpha stimulates NF-κB pathway via TNFR2 promotes cancer growth, invasion, and metastasis. Anti-TNF-α MAb significantly suppresses the tumor development in colitis-associated cancer (CAC) mouse. TNF alpha as a proneurogenic factor activates the SAPK/JNK Pathway and can facilitate neuronal replacement and brain repair in response to brain injury. TNF-alpha/TNFSF2 Protein, Canine is a recombinant protein produced in E. coli.

Species: Canine; Source: E. coli

Cytokines and Growth Factors TNF Superfamily Neurotrophic Factors TNF Superfamily Ligands TNF-alpha

/
HY-P71703 p53 Protein, Rat (His)
The p53 protein acts as a tumor suppressor, regulates the cell cycle and induces growth arrest or apoptosis.It activates genes that inhibit cell division and trigger apoptosis by controlling the expression of various proteins.p53 Protein, Rat (His) is the recombinant rat-derived p53 protein, expressed by E.coli , with N-6*His labeled tag.

Species: Rat; Source: E. coli

/
HY-P705518 Cellular tumor antigen P53/TP53 Protein, Human (His)
The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His) is the recombinant human-derived Cellular tumor antigen P53/TP53 protein, expressed by E. coli, with N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P72261 Wilms tumor protein/WT1 Protein, Human (His-SUMO)
Wilms tumor protein (WT1) is a key transcription factor that critically regulates cell development and survival by binding to 5'-GCG(T/G)GGGCG-3'. It oversees target genes such as erythropoietin (EPO) and is critical for the development of the genitourinary system. Wilms tumor protein/WT1 Protein, Human (His-SUMO) is the recombinant human-derived Wilms tumor protein/WT1 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.

Species: Human; Source: E. coli

/
HY-P7647 BAG-2 Protein, Human (His)
BAG2 Protein, Human (His) promotes tumorigenesis through enhancing mutant p53 protein levels and function. BAG2 is a target of the c-Myc gene and is involved in cellular senescence via the p21CIP1 pathway.

Species: Human; Source: E. coli

/
HY-P74657 p53 Protein, Rhesus Macaque
p53 protein, a tumor suppressor, induces growth arrest or apoptosis in various tumors, regulating cell division through gene control, including cyclin-dependent kinase inhibitors. It stimulates BAX and FAS antigen expression or represses Bcl-2 to induce apoptosis. p53's multifaceted role underscores its importance in orchestrating cellular responses, maintaining genomic integrity, and countering aberrant cell proliferation. p53 Protein, Rhesus Macaque is the recombinant Rhesus Macaque-derived p53 protein, expressed by E. coli , with tag free.

Species: Rhesus Macaque; Source: E. coli

/
HY-P85931 Wilms Tumor Protein Antibody (YA5623)
Wilms Tumor Protein Antibody (YA5623) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Mouse; Reactivity: Human, Mouse, Rat, Pig

Monoclonal Antibodies Primary Antibodies

/
HY-P82532 Wilms Tumor Protein Antibody (YA2277)
Wilms Tumor Protein Antibody (YA2277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81259 BAG1 Antibody (YA932)
BAG1 Antibody (YA932) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BAG1.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Primary Antibodies

/
HY-P811835 BAG5 Antibody(YA10306)
BAG5 Antibody(YA10306) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BAG5.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P811835A BAG5 Antibody(YA10306) (PBS only)
BAG5 Antibody(YA10306) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to BAG5.

Host: Mouse; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P81259A BAG1 Antibody (YA933)
BAG1 Antibody (YA933) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BAG1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81259AA BAG1 Antibody (YA933)(PBS only)
BAG1 Antibody (YA933) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to BAG1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82532A Wilms Tumor Protein Antibody (YA2277)(PBS only)
Wilms Tumor Protein Antibody (YA2277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P86440 Wilms Tumor Protein Antibody (YA6132)
Wilms Tumor Protein Antibody (YA6132) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86923 Wilms Tumor Protein Antibody(YA6616)
Wilms Tumor Protein Antibody(YA6616) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.

Host: Rabbit; Reactivity: Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-K0612 Weigert Elastin Staining Kit

MCE Weigert Elastin Staining Kit combines Weigert Resorcinol Fuchsin Staining Solution with Van Gieson (VG,Elastin Fiber Staining Reagent B,mixed) Staining Solution. Weigert Resorcinol Fuchsin Solution is mainly used for staining elastic fibers, Van Gieson (VG) Solution is used for collagen fiber staining. The principle of VG staining is based on differences in the size of anionic dye molecules and the permeability of tissues. Picric acid (PA) has the smallest molecular weight and preferentially enters dense structures. Ponceau Red or acid fuchsin has a relatively larger molecular weight and primarily binds to collagen fibers, while light green has the largest molecular weight and stains other tissue components. After VG staining, collagen fibers appear red, while muscle fibers and cytoplasm appear yellow, enabling a clear distinction between tissue components.

Cell Biology Cell Analysis Staining Kit

/
HY-K3125 Extracellular Vesicle (EV) Ultrafiltration Concentrator (500 μL, 100 kDa)

MCE Extracellular Vesicle (EV) Ultrafiltration Concentrator (500 μL, 100 kDa) features a polyethersulfone (PES) ultrafiltration membrane with a molecular weight cutoff (MWCO) of 100 kDa. It provides rapid filtration, high concentration efficiency, and high exosome recovery. Its specialized anti-dry-spin design effectively minimizes sample loss caused by excessive centrifugation and membrane drying, thereby helping maintain high exosome recovery.

Cell Biology Cell Analysis Exosome Isolation, Purification and Detection

/
HY-K6012 Tissue Dissociation Solution

MCE Tissue Dissociation Solution is able to gently and efficiently dissociate tissue samples into cell suspensions or cell aggregates, which can then be used for the subsequent construction of tumor organoids.

Cell Biology 3D Cell Culture Organoid Research

/
HY-KE7004 BamH I

MCE BamH I is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7006 Bgl II

MCE Bgl II is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7018 Hind III

MCE Hind III is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7019 Hinf I

MCE Hinf I is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7023 Mlu I

MCE Mlu I is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7024 Mnl I

MCE Mnl I is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7030 Pac I

MCE Pac I is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7032 Pvu II

MCE Pvu II is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7043 Taq I

Taq I is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KE7044 Xba I

Xba I is a restriction enzyme for rapid DNA digestion, including plasmid, genomic DNA as well as PCR products.

Molecular Biology Restriction Endonuclease

/
HY-KM0010 Centrifugal Protein Desalting Column (5 kDa)

MCE Centrifugal Protein Desalting Column (5 kDa) is a prepacked desalting device containing resin particles with a particle size of 57–80 μm. It efficiently separates small molecules with molecular weights ≤ 5 kDa (such as salts and buffer components) from macromolecules ≥ 5 kDa (such as proteins and peptides), making it suitable for protein desalting and buffer exchange applications.

Protein Biology Multiple Fluorescent Staining

/

Références

[1]. Druker BJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.  [Content Brief]

[2]. Lynch TJ, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139.  [Content Brief]

[3]. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.  [Content Brief]

[4]. Kwak EL, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.  [Content Brief]

[5]. Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.  [Content Brief]

[6]. Cristescu R, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. Ann Oncol. 2022;33(9):914-927.  [Content Brief]

[7]. Wan JCM, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238.  [Content Brief]

[8]. Siravegna G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):795-801.  [Content Brief]

[9]. Schilsky RL. Closing the gap in cancer genomic testing. N Engl J Med. 2022;387(12):1145-1147.  [Content Brief]

[10]. Kato S, et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020;11(1):4965.  [Content Brief]

Keywords

cancer biomarkers | precision oncology | targeted therapy | companion diagnostics | liquid biopsy | ctDNA | tumor mutational burden | microsatellite instability | molecular tumor board | genomic profilingα